var title_f17_20_17728="Lentigo nail";
var content_f17_20_17728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo of the nail matrix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17728=[""].join("\n");
var outline_f17_20_17728=null;
var title_f17_20_17729="Gram stain lesion 1D answer";
var content_f17_20_17729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridia in muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtLnTbURR7LWEFAAP3aj/PU0wwqcDyFJ246CpY8pIGVjkAk55zVhL6VAnmqrAdwMV+MRak/edvxPs/3lNWirleHTZblF/cIqg8M/A/Ct+3jSOBEXJCjGWGCarWt1DcKijcCDuweMGrrOijLMBivscpw+FpRdWnPmf9dDwMdXr1Zcs1YRgMZ6YIpSAchgCPeq0t7GMrGpk9e2KdBOZeNpRuwPevRWMw85+yTvc4vZVIrmKN5pfLSWvU9Yz0/A9qgXTrnAZURD3BIzW0dwHOKQlupriq5HhakuezXkdUMxrRjy3uYM9qYiyyOr55O0dKrABWT93nnHNbl9aRXaHeXjkIxuU81HPDZ2sSySh+yg5PJ/CvFxGSzhKUoP3EdtPMrpRa1ZiPH5bco6k8/M2TQw3KQWDZGCGHUVJPL50pYDCAY5/xojQOQXOFB6143LeVonpOfLC89BixeaMplvLGBHn5hUYyHCs3zkZNXnhIkUxguvZ4/vD6+tRpFLM7gyJ5oXdsIwzCt/q83olqc8cSk9dir8rDgDn04FKYnI+YuqEZ+tWvJCAi4gMPy5U4JGeeD2qvLI8hQKBhBgelZThKGktDWFbn+HYjQojNhgwHHzmr0U9mnKNIMgcnkfSqLqWB3YA659asWtrHKUjllEZfO1MZ/OuvBVasJ2patmGLpUnHmmWLto7hJba52PYzIUZt2Qc9QRRo9lBpdktrYSSNACWUSSGQjPYEnOPaq0pt7VWtlYTSNycDAB9PrUt7JNpVlcTxW01wI4i/kx8sW/ur719FhsyxFR8jXure1/8Ahjxa1CnFXLvmypKVZd6f3unap9y98iqOlyNeWUVy6OhlQExtwyEjOD7joamtopFlwH3Q7cc8kGvSo1qsWk1dM5Jwi/UsgBvukGnbGHY1karMjTeQEJdR0DYyaoRSXEB3x3EpAPILHb9MVxV8/hRquny3sdVHLJ1YKVzpMU4DJx3rn0u75XwJeSMkEZpDcXkgUtcvhjjAO2sZcRwtpE2WTzvqzpRE+M4pMfNtGS3tXKhZeC1zJ1wQZMkfrUqi7Xpdye+JP/r1k+I/7pusnfc2NVvDboI4WAm6kH0rPkmfaDE7GaUdOgqB/PdsyXDMffmgLN2nb25/lXgYzFzxU3KT07HrYbBRoxS6jbeLyLhJAm+dCSMnGT71q2NhdvexXkqo0ZJ3q+Dj6VnCO4XBEjE9uKu2l3qIkEQLMnU5UD9anCTpKqpVtUGMjLkaps25pMMPTOOvSm7vnO4EUz7VDJD+/Cq390EGg3Ssp8jAk6Df0r62ePorVVF6Hzyw83vEnRgyZRlPuDxVWS9jVd+AQrbTg9xVdZBAWhmuFyxz8gxz6VPEqTRSNJEkNsPu7+re9cdXNJ1tKLSaRrDCqHxok/tK3LBUSV2wCSq5A/GrPmptDElQemawywilO2L5BwSjfeqM3aCRm8vCngICOPeuGnxBXV+dJnW8tjL4ToVdC2N4p4+bG05rm3mlmVgrCNRyrbsGr0ImdWWaQlmXahDY59a66PEDm+VwMauWuCu2azDHBFLyT06VmWdvPaESXd5Id64CO2Qp9aW6vXi2hJlbjtivRq5tSpRvP7jmjgpzlaGppAZHy8mlCMAP61z019dOuBKYx7EZ/SqzF3PzPI5/2iTmvOqcRx+xC53U8mnLWTN/UdsltJAj2xdxtZJTwVP3hx7ZornfJGS2zn145orjln9STvyo6Vk1tpFxTE0QVkIYd/WoR6Y4zV2/kSSQGMhDjBI4JqmUxkEc14Vemqc3BO9jsw8+dc2w0blOUyGPOc1LAJJrtQ53FurYxjFRDG7ndj1qWzfy5yyOQmOffmilLlkrvQrEQTi3bU1pYEBDBePapPKwVKjgdarzX0cUS7VLEnp6CmRaizq2yPJHT3r66OMwFKe+rtt/mfOuhiJxvbRF0sfMII4xS1Ed0ah36sOdxApBcwtKIhIu89s/pXs0cZTekpWv3OOdCfRDyvWq95ALm2aJuM8q3oexqyfvbSRu9M80mD8wIxW1SlTrxcO5mpTptMyrfSwMG4kD47LwDWgsUaR+WqLs9CM5pWGOlUhqdl9v+xfaojd7d3k7xux64rloYLDYX3eVa9TWpXrV9b3JY7SOIHy2kU5yBu6VUvbWUSLNCGkfvggMK0uCARTe5Ofata+WUK1PkSt6GMMVOErmBLc3YJWaSZT6MuKhclwBJgjtXSPhhhwCPeqcmnwSEkEq3t2r53F5BXT5oS5vXc9bD5pTStKNjHUklRgMFP3TVmC7jhZvMjYJjhlGcVLJpsoyUKuKhNnNENzRuqjng5ryfquJw0uZweh3Sr4eurXL9jHaS7poVDsGySRyDV05NZGnSC2W5Y8SPjA7d6sSXE00MnlNsOCOmDX1GX42jDDL3fe6pHiYmjJ1LJ6F0KAMDAHtVK5mkgkjjgjXDN8xNLHckIipGgz/AC9ae0wfPyA+4NdOIxVOdO9N2aMadKUZe8tDPuJLaZjtZvPBwzj5cj696qHyxEdqMfMOQN3T3qaW22suxiAAcj8e1Pis14MxEfGASetfG1adWtVd1qfQUalKlBakcRiDbjE3yrjh+tRSmPCrHbY4ydzk81I1vFA6LLIAQezGmFEGNmSfUmuR+67M7KXLJ3Q3ccEMFx6AYpQsZ5K8n0pTx1AGBxRjn5cCkddkSfJ/dK855NLtHY/rUbAg4Ug/SnopYkmpLtYkVnUgq2P5VKJ3kVklLBSOgGc1DsGMByPrUsaOwIjdJu7DPOB6VDsZTS3ZHggAZwBTkyW4c/hUsbcE7NwHr2pVeVzgCPH93gf1pNi6aIfFIVY5gcnuT3+lKzQBs3LO56CMHoKbiXBBcDI52kZpsdshziTbnpxRGfL1M3RjL4iUT2ouAUjwB2LdffippJIZgzrDHk8e9UXMauYg4bjPOMmkUAHKkKKpTdv+AX9Xi9UWxEzYG3y1b1wavQQsl6ittICfLkcVlCSTI43emRWvpfmOHEgQHGAAP6114CKnU5ba7nFjE4LVmZqErzXRL/dTjGf1qqQN5yFwo3elXZIl86RfNiLZ6FsGo3tJ0VnYw88cMK5akm5tyZ24bkjFaEMaA5ZU5HfOKlW2crywOOeh4FReY8f3SAT6HNKZXf5WJOTtArPU3mpP4SZbQdHmCkjOTwAPzoqFmG45Ayeg6UU07bmTpVH1JpoSiklgQevPSosluvXoDT/MUkowY7u1SPGrRlkJBXqD1otfYwhPk0kV+T1OO3ApVJYMCM+oz1pGB3YIwR2zjFCMULFQMkdOuKR0SV0W4IY7hPKCgcjDDkg027tZLMqEZ5FPtSW0z2wLJwwHfGKdJ9r1GMLG+VDZJBxiu2l7GpR9nyt1L6Hmz9pTnzX90rmBgAWPvzUSgkEqBgcntWrfRBbNYnwGK4z1waqWdmJB+/clcfw8Up4SpCqqP2tCoYiDg5vYqNtJLEkOec5p/nXWGEM0xx9TVrUo1ttOkNjaJdXaj93EzY3H3NIkTHaQyRPxuUHgGuuWAxWHSknv2Zz/AFqhVurE0F4yWSefmScHDDgH61k+INI0/U5IJ5V8q8i+aO5i+WRPbP8ASr7Wqk5lBJAxkNnNPeBiVJyx7EcZr0o4rHTgoP7zj5KMJc8dx1lKYrSBHkaVtu3ewALEdzip0m3dF7461XdJwrbggd+cKcgY4x/9epIwDncAGXghSeDXsUK2IXus4KkIPVCybjg4NLtcgc/lVWazSW/hvBNN5kUbIqCQhCGxklehPHFRXF15F3DAYriQyBm3ohKIB/ePbrxTnV5Hdpu/mSoXWhdV2QszsAqjpVaS9dgFZGQMcDI60krhIZJrhz5KjODxisFtTj1aCG2sdQ+zTzR+fGIyvm7A3UKwPGRjOK83E4uSWjaj9/3nZQw/NqdQslvbIGOFYjkkcmqFzqHn7l+eFQcgr1IquRHHaS3V1OqQRjJdjuOfoKz2k1NtStpbCK3fSZBtnE6tHOnX51z26fKQK4auMxFeCUbRj+Z0QoU6bblds0hcxoM+bKzAjAxkfSqcM9yuovI+37Mw+6oIYH61eulETRND8ySD5T/eNRKs8hwsa4zySwGK86VerCXIzrhRhOPMiRLiIKVMbHcc7j/WrCSqhPkuHT+JcdB7VVNtK5lIUmNOQcj5h6iobURTTJJuY9RgcA5xz+laU8ZVpPmaJnhqc0+Vmz9mhuRhsZxwCB+hpn9kJn55XweynFZbjdJIsrE4PGDwBSx7Ap8qRwfZjxXRLH4ecr1KWvqZwwlaK9yZpvp1oqjeZlGfvbqSPSYGZsXUrAHoAv8AhVWK5liGVuH+j4ap4754xnaCCeg45rWnisvk/fp2E6WKgvdkRXOnSwzkRRtLF1DA4qaDTZ3G5gIyf7wzj9atJqO4cIFbHdqVdQLBvkBKjPU/p601h8tc787t2G8VjOW1iFdGc/eugP8AdXrSPpslvMmZTIhyCyDDCp7S7ZnYyRlUIBGTzn6UaZrlhqKStbvIvlPsYSxlTkfWuqngcBiKXNHT5mMsViYys9ShJbMp4eZz05SkMDkA+VOV9dmf0rpEYOMqVYeo5p2SPakuHYSd1U0L/tWcVZo5YxRLKA0pGB3QirNvaxytxdME9iK6HORyAfwqlPp1nIxJj8tm67DjNctXIKtN3jJS9TVZopqzVip9jtI0wl3GCOMuwOaqzW0ecC5t2XqNvBq+2jxDiOaRPTODUcmjyknZNEV7ZBBNcuJy+vuqVvQ6KGKp9ZlRIHLlVAPOePT2q4Jyu5o9xJHr+lVIQsUoEowUbBBPemTlljaR2xg4wK8nmcfdWjOxw9o7vVDfLyuJEO48kMOv/wBalEEPQpKe+VIA+grS+xSssD27F1OC6vgYFaBhBjC7FHqDzXfhsrr1ruzWl/U5a2OhCyRzzeWrARxFeOjnJzTGUqqtK5B5wAeTXTPGjLhkUj6VCLKHI3Lu74OK7p8PV0/dkmZQzaEVqjmx024OD09RRXUrDEgxHDGh9Qooq/8AV6qvtf195X9tx6RKU1hHLKHDFRnOAKqXUEq7TFH8hPPqDWgYY4wXlcqo5znFYtuzwxtHbzzPHvZ/Mmbc7bjnA9hnAFPM6OGppuUeWT7M5MJOrNpLVIc6COR97FmHB4plqVW4DNgxg85p8Y3lmkbJxyxNPaOBSNzsV3ZyRXz9ODbv0PVnVtFxe5LfxWVuY0NxGlxOx8qFnAMhxkhR345q5ZiSKDb5RznucVT1KxtJjZXb27SzWz+ZA+BlTjGfyNKt9O7Fgny4wMHPNfRueFwlaNSKfNbVLb+rHkWq1qbi9i5cwyXAUEKgHvmo44QCRuzjjp0qWO4EkHVfMx0FSRjCg45xzXsU6GGxNRVYO7a3OCU6lOLg9iIwAfeZjj0FY+i6t/aa3Lf2Ve2UcMpjU3kYQygfxqOuPrW3I2WwB261BOcLjqa2xEKVOnJwWvczg5ykkys8mGPGATnimNcsM5PGOlQybskZNQthuvzGvjquOqqbcXY9mnh4tai2BNu7+c8k7OMF3xx9P89qvK5dflwwxyCeaz2O9SmSFIwakgcxyHAB5wcV2UM1qyaVV3Ma2Ejq47mioOegCjgYpsLpKW8tgwBKkg5AIOCKh1G9gsNPnvLuQxW8C+ZI5BOAOvSl0pbY2onsWR7e5JuFdTkPv53A+hzmvqaSi1d6rv0PIldBb2IiZnknkldjk7un4DtWbqWhWct7aX8tkkl5akrFMnDxqQQRx1HJ4q/p17DfPPJaXkNxDHIYSIzu2Ov3gT61LceXcSCKV5MHoF6Z9c1ljMPSnTaj7rf6l0qk4zvLVIyWE6RMRGqwPxlsl92fyHFK1vMsojeNy55wWwDU9/aTxxTi1kGHUlSVyFbHUj6+lR+HbvUUsLZdZELXhTErwElCw7jPI45r5lYVKoo1/dtZf8H0PU9u+RunqW7u1N/aoqDy/LyFz147is9tLaKNDMzyMTgjgY/GuhDRsVCyoSeAA1OI6hhweo9a+gq5TQxEW4P3u559PG1aXuvYxESQWFxDYyfZpNvysRuYHr360kITyEKqpmwBJs457nHatFrBACYSVY+vNU20y5GSGSWTOQ5+XA9K8bF4HFRpqny3sdtCvScm27XEhEdxCx2+XJHxjj5/cfyqEiPf93apGDx3+lSIjrlmjYFSAVK4I96l8uWWUBGgZPRh81eRUi6js1aR3U5cmzuiqEVuhHHOOamWN2s5AUxKsgcL3K4wasSW7r/q4hkHouAWqhpN/DqGo3yW0U6JYzeQ0r42SSAZYL3O0nB961pYOpZu2gp4pO2pJuBHOTTsj7oxu9Mc1Jd2aXskEPnNDtlEqKgxuwOh/nVy5jtIWCSzOJCOWHJ+tH9nTS5nJJeY1i1J8tjN1q/k07RnuYbC41GSFQfs8GN7c9ie4HNS2aw30UFzHiKN0EuyQFWYHsR1BFXNKsZ4kIlmE8TAlZQMZ54z71meIvCmmalMt1cXE9tdIoCyw3LxlMHPAB68+letTwnuqVWyXf8A4HY5JVPftHU1kWFG/dqFXHHlsaXzpEwFmlA9WANVkeBEHlLI5HHJwTx1zTJJA/RWHqCc4ry5ZhOnpB/cdcMJz6tEsNvP/bX9oHUHaMw+Q1vt+Q4YkPjPXnFajlycqhJB9MCslWKjGRVi0aRpMJcY56McV14bNpVbU6l2YVsHyXki3JdeSf8ASNw98cfnTJLyHA3Mfzq3cQLPC0Mh4buOx9axn069iU7kEqesbc/lXXmE8bQf7vWJnhYUKi992Zbaa3nJR1QsfUZNVpLIhiQu4DoOozRAsivxGVI67hyPrU0zSLHtlbg968KU1Wi51VquqO5Xpy5ab0LbOFtVL3BhES5ZlOMfWnWl0k8IkhnjnjPSRSDn8RWVHIFBUgPGflZW7im2Rhso/IsraOCAktsQd+9ejQziEILdNfcc9TATb20NzzvYH8aRpQBxwaz0kUufnC5+Yj0qQ3URZRvBJGee4rup5w5x1ZzTwfK9i15nGP1NFVGuYtrfOAg5LHgfnRVPMrOzYlhW+hl3E73TZdvlHbFN3Bfu9felxkcD+lQwXMH9rNYybzciAXCqFypUsV6/UV8qlUryb3Z7zdOjGxdgeRJI0UrhuXBFXIjbzOoMS+xqnEzRSNI4KNjlSOaig3GdnTKZPQ/zrow+Ilh7LfXY46tJVby8jduYvMtmVMLxyQO3esszRtp4WMBSjcY74rVtnb7snBxnrnNUbq3ZkKgbV65C8Z9a+gzSm6lNVqUdWrNWPNwslGXJJkOjumDFKFLD5kz1q5OzSoBAOOD6ZqlZ25V9+cOOBirrlYRu3ZPTAoy+c/qvJU0XfyFilH23NHUpXF2thC81/NFbwqeXcgAfjUcsg6hmYHvVXV7G11KaNr6GO4WIho0kG4Kw/iwe9OyfcAdsV5GMxl17ODbS7nXRoL4nuNmL4OMc8GqWralHpmmXF5cBzHBGXbaMk47D3qeSST7VCiL8hBLH2Hb9anm2vGqyIm1+ArEfN+fXpXBBXknJXOuS5Y2Qy2dZ7SCULIkkqBtp/hyM4qKWaOOZUeRVeUkqrMAWx1wKr3Y1FLy2jtI7SS3JzK8krBlXPRVA5OO+afqem2OprEt/axT+S/mRbhzGw7qeorSVrpy0XkRFK+mpeguGi+Xd8p6gjOakW7AQoY0CfdAAwMVEFUJ0ye/GaNmSCWJAPHFbUsdiKaSjLQwqYelJ3aKySRaUlhZ6RpqJYFyJDGwjWIdc46sSTW4GilLIkmWIzxWZLgHOCcdsZH/1qgt5NO0a1vtYuGaBHw1w7OSDt4B2+vbgc19Bl+ZvEVPZ1kv839552Iwns480DcjZVJQtyPXqayPsl9/bV5JdtAdLaNUhjRP3gbuzN/Kql/cWniDSrPUtInlPkzLIjBGjLYPIIIzj8K1UvpmjyYjGcdTyPwNepi6mGjT5Kmr9Njmowq35o6fqZH2byAZLdy0Q5DDp+NaFlqwcrHeKMjlGHemm8kBKHyypHKleDVaSCCV8KDDu7/eAr5GOJ+r1ObDyZ7ipRqwtWibaXkRwGJQnoSOKtLkjIOR7Vgw2U8IBWVJ4CPuLyR7iopprq0wVt5WUHkqele3RzqtBfvoXOCeAhJ2puxvT20NxjzF+YdGHUVhzQGNkPkTYOST1x9cVa0vXLS5uXtJZRHdKAxRuoB6fniteN1YfumVl5+6c1vXwlDMoqpB8r/EinUqYSTjJXRyNjDJFq95exXE07XEcaCFjlIlXJ49Mk5Jq/oN/pdxpiy2CobdZHx5aFVZicsRkDOSTyOK6ExqT0Ayedoxn61FcWiy4K/KQMAYrNZdXw9KVpOT0t208hyxUKsldWX4lGW/mlBWKMQr035+b8KqSs0khaT5yep71YmikjyGjZvcVDKQq5xyffp9a+WxUsRKX7657GF9kvhER2QECRgvopxSbuc53DOd3vTdr9R8w+uaVGAJ2jr+tcrbatc71SjukSBv75xjp6CnSLsOX6diehpnJ+lKjtD8qLvU/wkbgfwqLDlFrVAXLfLHtL+pPAqcR3IO6IRzIOTsOCPwpwaNbaRJZNjN12pwo+nSpUsv3TXFvOS4AwRzXRToub93U5KlXTXQkj1IRr5MyMrkYBzzmoLW+vNrZ2T7SQR0anpe3AGLqISp/tp1+lSLbWchMxkMJ7ZONtd3t61VqMaj076HMoU4Jtx37GXqV7ffbbSXTYbVS06i5e43fLGOu0Dq3YZOB1rUa7jfiRYyx5wBUcz27XXzRfux/y1jPLVXe2iDlrZ32dQGFctTE1Ix9nzaa/M6IUacndqwNtydhzkk8jpSoAD0zilKbR+8BYf30/rQjRlSQXwBk/LnFcUYym+WKudc6ihHUcFfeMJkD7wA5P4VX0zSN2tT6nNeTuvKrEzjZGPQAfStTT4vMYBoXCyAksw59qNX8uC0WCIFVfOcDtXs0MLUwlF4iXoeVOqq9RU4lHU1TUoZ7ORUFt0yrYLetFR20BKfIhfHOM0V5zxVZO6kzrdCmtGLJJ5k48vakZOAM1s29vFAwkRcybApc9celYkCr58e5lZuoGau6nqNtpwRr++htkY4AkcLn869nJ5RjKdacbvocGNg58tOmW760hulLqdspHDDvWeqmKJUlRdwz83anwX8F2P8ARJo5AOSytnH5VY5yOFMZ7mtsXGliJ+0grMxg6lJckxybjIjnBQDAIqUuedvyr781VRXjcKufLOcDPes3xTqF7p+jM+lRQS38hEUKSsFUMe7cjgdeK7MJWbXJbV/19xhVgr3NnIUdzmo9oI9utEEUggUysGfYNxHAJxyQO1ORBgbFIrq9nzK1tDHmtqQeVuVlCiomtyM5xn0q4DgnBAx1prnnLNXLUy+jON2tTSOInF6GTqFo8tuUgupLWQkYdFU/owIxXIw+GdWfxha6tq2sJcWtpkw2qR7AH2bQ3Ujux/EV6BLbs+0oMjryaovC2WEhGfRetcFWhWwqkqUUk1a9tdezOmnWjVspS2KVzcwWiCS7ljiXOAzkDBPvVm4VdiOPvHIauc13VtMfWbTRpLK4v75pY5DFHDuWAZ+WRmPAAwT+FdWtq0mBHKCCCRuHvXHDL68qa9x69/0OiWJpRlo9tynu9velyzdADk881n3pj8N29zqviLUg1snCxKmBycAcZJPParFtMLqCKdUdFlVX2Ou1lBGQCD0NYYvA1MI0pu/pe3ob0K0MQrxVhZr2CKeS13h70W5uEtl+865xx+OB+NYur31udOtdF13TTdahqMe7+z4EMigDk5bgDHHJxzW9EyJKJGUtsByQcc+lXhNaNcJdSKBJEu3cR8wB7V6OV1cKrqppLo79f6+fmceLp1U/dV0ct4evtL0qG00squkyvGBHaXD5CHpsDnhj7Ct4u6MRKzMCemMACs3WtKt9Z/taO5vFNndWpihRYvnikIOX5/4Dj6GrsLtDbrE7NJhQWL9SaWY1Kcbezldvfr+P9eosNGc90Rt06DGTgimlsDI/Gj7rHPTrimlh1/WvGPYhDSw6GYRtgklT1FTyXl39qso7D7M0Bk/0oyyHcqbTjZjvnHWqRZSflOffpUMcMMV5Pdhf38qKjHPBCkkfzNelg8a8O/eV0YYjB8+sdDR1+8j0q1+3XSmRTLHEvlRB3Jdgqj8z19K5vxNHe+GGutXvZGvNGiljnWSKb7PLbkttZSFAEiYIIzz25roIro42K5weiA5NbViq3FiIriLeo4KuvBH0r6PL8RQrzfJC39dOx42JhUo9SjYa/bXskMdldQ3Tzw+fGEcHKZxu+nNayXLgEuhPPy46496rxaXZ20rTQQxx3DLs8zHO3OcfT2qvc/2lFdwkGB7Iht5Jw+cfLg8ADP1rdxq0dIzv6mC5KvSw3TPFuk6jrl3o6SyRajbZJguIjGZF/vITww+lat5axTwOUQGUKShB4zjiuJ8ReH9Q1h7K7haxTUrabzI5bq33PHH/AHMqwz9fQ/jTvC3iYTxSfbrq1N7BKYXSy8yROCe2OD147Uqk4V0k4cy697/5Dpwkm7OzXrb7zbtra7W0jkntnjfnciEMB+VLqVpcQWcs8Fu8kiDKqp+8fStiO7LNzGwXAO71B9qsJOhI+YAnsa8v+yMHUk5QnbyO2OYYimkmrnLWzedbRvOBGXHKFuVPoasxq6jdsyRwvNXtR0Kz1XVLe+uWmdrcFFj3kRnJ5JXoT70y58PNJexzWup3VlEmP3MITawByQcg8H2rGfDcpNclRWfdPT7r3N1nKt70Hf5f5lZJJouGi8wnk/ICfy606GeS3lLQuiBuSjA8fhjit24tYpeceW2MZXioE0qHB8x2kyc5NcksjxdOfuW9U7FrMaE1eaKsepyMMNbq46ZDYH4VBJPG3zSIyj+6GH5Votpo3/JI2z3NMk0uRiNrKB656VnWy3Hyspq4QxOGT0MuWWOJA0EW2MDLZYngdaS3miuIkmt+FkAYSKchgenNbY0i12KJGkZwRk7sA+2KgtvD+nWKSJYqLZXkMpRT8u49eO1KeSYiNNzluXHMaV1FIoJJJEoMjZH95e1W7fUCpCLICpPBK09EWEt++H0HOaoW9xHeXl5CiQvLbOEcRn7rYBwffBB/GvOp0asZ/u9/I3nVhUV5bG4L6GCAm5lJPUDGKz7q7tb0+WPMRl5GehqDWns7OOFr1mhdj8rfeA+tSRafiPzZthj2ZDKevpXpV62Kr0/YyWi/Q5aVOlTftOrFANlZszKCZPlUg9KKlzbW1nuuJkSMEnEnI+uKK5J4du2vRG9Oo3d8tysl5FCxAhSJz12qQf5Vyk/grw/qF4Z9Timv5A7OFuZ2ZRuOcEDqB75rtWW3vEDOo3gYDDg1nyW7GRUwsTKcqSR81ddWtXoxU6NS8X23+Zz0lTleE42ZHZabZ6baNHodlBAyjKwxYjU/XArQ8wRBmkwzf3R61XkC2qt+8LSngAdqrliw3HoOST2rOpjZ04pOK5+4QwyqO6ehNcXv2W2luRBLceWC4ghwXkI7DJAyaydO0WPxBJLqet2vm6fdhJYdM1CJXezkAKsQ2TgMADgVoxyMv3SABj8a2LFGFnyuAxLACvVyHFzlJ00td79V6djkzCgoJO+nYytQ0GPUNS0+eS7uY7Sz+ZbKNtsUjj7rNjk7ew6Vsk44FU9Mhu4YWS9lWYhjscDBK9tw9al1G4Nnp9zcxwvO0UbOIo/vOQMhR7mvpI8zjZnlysmSeWTnBrnvF9z/AGfYoyalYWE8riOKS+GYyx5xjI9PWtNbuSSeMAFN2Bt9D6VW1OK8lv1tjbW9xYMm8ySudyvu6FcYIx+orioV6Va7gr23NpRnT3drkOhahdNH5OoPbPdRkLI9u/7pj/sgkke4NWtP1nTNUa4/sy8trv7O/lytEwYI3pkcZrNPhnTrdtVu7GN4pL6MifyycNx1C9N3vjNcf8L/AAjfaRq99cxz3SaOyqsVpcQLCzOP4mVRg47N1PfpXZCMJQlvpa2mn6kSlG6vueoxpAjPP5caSEAM+Bk/U1WSSKG7mAlVpH+dU3Dp9Kz/ABNqiaTZWkzJFLbz3kVrMWbCoHbbuP0OKvyLEhCKAmwcDoMegPf6VjiqkqdPmt6BSgm7FS+xIWaTa67gRkcAjpjNQIrPJsTLPnPHNS+YA2GiEigkgE1aiudqBlhGWTcrJwMd818Q3HEVL1JHuxbowtBFYW8killjJQdRjnNQlX5AAOeuDV9byD7rSbXIziqtyojZyyKfcd6jEUqcFF03cujUqTdpETLzllPGc8YqB89weAM5qUFmIJJyDxSOMvx09+ce9cy0OpJLQYsZdGbdjHAB7k1GyY6inDggjvz9akyD0qr2Gm4lQR455FWbG1FzIS7MYxzjbxTGGdxPPOQc0kP7mQMMYHoeldGHnCNROoroVZzlBqO47W4r+zhsn0NEytwPPQqMtGQQcHseh/CjUImvreKKS5u7fbKspML7S6j+A+x71dXUGRfub/51ULbpCVGB2Fe7jc1pRUHhNGvI82hhJz5lVOitpIriEAAcjBWqdvZ6fomnxQRvHa2EZIAmk+UbmyBlj6ngfhVG3klhmiaMKQD8wJxxWveWNhrMES3lulxDFKsqrIuQHXoce1erleOjjYWqaNb2PNxdB4eV4jpLXeyqxbCnJwSA3scVxelWes+H/E17YW+mQX2l6ndveG8EnlC2Vsb0ZcHc3cYxnJziu/VGBOTnNO2Dg4rsp0VGNor7zF1GccfBlnLqVvqFle6hYzwuA2yZiJYw2TGwYnKk/l2rf1GzupJbdrCaCJVf94sqFty+gIIx+RrTCjuKwPEei6hqN3bXOma5daZJApHloivFISQQWUj+XatJYeNW3tber/4Goe3kndX/AK9RviT+2YbMRaNFJI0h2tLHKqvF/tAMCG/Sl0PWLsW8VpqscyagMjdNHtWTHcEfL/Kt+N1xhiNw6n3pXVM7mAOK5Yx5aXLSlp36/wBeRrze97yOa8V+Jo9B0W5v7pwPJKDGxiAzMAAQOTnParXh3xC+rQSmXTbu2eIJ87JiOXcu7KHqQPcCrq2FsL25uTCrSz7PMzyDszt4PHGTTr+V4bXJZ0LfKuPWuWeMeGoSb1ff7uhpGi6tRJbFn7UOWKMqj+JqwdD8Z2es6tNaWNvcy28YIN8qjyN46pnOdw9MVQuLnVLpNRtrOJYhEnlwyz8iSQgHdjuoz+YqjYeGxpcN3baRcnT4L6Zri6khXMnmEAfJnKrnB7fSuLD53Bp+1dn07fO34HXPL2lodfqurNZRb4LcTDcAWLgYBPXnFZV/4pgSSITXMFqsoJj3SAb8HBIz1/CsrWvDx1DTNM0mG+mg0+3kV7ncS0twg5CFycjJ61q2mjaQZVnfTo2lji8hGcbl2bi2AvTqfSuOtiqeK+Os9b6JfcaU4exWlPbv/TLC3UkqHzVGV7ulQ+Foh9vvb9JoXt75lnSWBcp90DqOvT9Ks6/dCDQdSkcylEtnLiADeBtPKg96i8AW1hY+D9Mh0e6luNNEIaB5OSVPI/nTy/ApRlWVTqla2/Xf7vxJxNfmajylk3Wi3+pyW0t1BNfpHu8nd8+z1A7irUrs8Zht4lEaYKHsR6GoZ0hiuYmjSNbl/lQbR0781I9wRmOWJUYdeTitcVXpU4uNmr9e5FOE5NMz9SWOa0mlns5LsopxaRsMyfieKKsGeRQRDIgH0orz8PmdChHldPmOt4WpPW5QikaJ+Pu960PPimhCyIc9j6e4rNIz0+9U0N3GFSJgSXzt4JGRXBh686T916M6cTQU1e2oPA7NyQWxgYPOPemNEwchxg9fap2IjjMmRjI49KlW4O0OUJI43cHFCjS+22jFVKiVok1jYKMSXC9DlV/xq3I4VsKQB6CqJvZmGVwAB371D9odmy/zcV7cM1w2EpKnh4u/Vs4JYWrWnzVGXWmYY2jOfWo7m5WOGTy2yx9D0rGgtmj1me6F3PsmjVGtycoCM4YdwcccVeuHWXbGiEDPJ9aiebSdJxi9wjhEpq6K/wA0bo0TfMvIJ5qwL65JbCRKxHLDJzTJ4XjVTjg8ZFRKxVuQCCeQeK8inXr4ZuKbVzunCnWV7XsXILyTzbbcD+8Yo4RC2GwSCcdBx1qniXRbe+vNW1XdE7l9821I4V6BR/iTzU0bfvo5ICVIxuHqPSsrWPD8niXVbK7vr23udJtHkdLFY8o0mNqlmzyVO7j1r7PLKqxmHcZSs113fy82eJiYOlO6RQ1e7TWU1LQfskElnPpwvIJRMD5pycEgDK84IPPf0rc027lurC3u3t5YGmjDGGTqh7g1agiE67o7drQqAASoBZR29h/jWVZX91cWCm4iFvOlw8ckTtuygJwVI7EYNcOP5o0nGWy89b+nmb4dXl5v8jQgkEcqkgYB6HjIIqu24SYBxtZip6fjUrsCv+rCgHggk4qPcuRtJz3z0r5ST6I9qnHqS7Ld41aZ8MfvBe3/ANam3Ns0MauGEsBwd69j6Ypo4J680+MsqsF+6eGB6U1NWs0HI4u6YxQdxz6/hTZRw2QR3I9qfgqvfGOO/FNmGAcc84GfqBWS3NN2V3X5uck9Tk96FyMLgemelOk4JGOhbI/wpSAc5HAOK0uX0IyCg5G0+tNA2k/LnIp5XIUHPzDIBqURDYCsirtJzhclvTFO4nNIrjjaFBLHgAc1IFdZlV4yO/Hp9KtaUsIuSPLZ/kABYcg96NckuoLy2itIUcTBjI8j/cwOAo+tejSwKnh3XcrWOOpjH7T2SQ6MlJWbaCh4O7jaKtLdSAFYDuXHy8cVnyLJcEmXHAHygAc/40xYTvKCQQuP73v/ADrjhiZUv4bsbPCxqK8jSF9LETuZNw6A0japdltwlQY/hVev51Wc5bBLMBxlhz+NJjBG047U/r+ItbnY44KlbY2LC/FzL5MrjeQSMDnNX3UEFT9K5aSUpNDKrcxkHcByVzzXVCRJ1EkZypr6rI8a8TTdOq7v9Dxcww3sZJx2KRiZJsZPlj7oz1qUNIJFRoztb+IdB9fSpmUE5pwr1aOGVJtdDjlV5kRTYjjZz0UZNY7bnkclxIshztJzgHtVvWpXVEgUBUlBy3piszT7U2tpDAZ5Z2QcyynLufUmvkM8xEZVnSj0PZwNJqHO+paRFzggr69/zpDHycc4pV8q3dsE7mO5sfSm+YzSFgTjNeLLkSO6PO3cQcrz19KlixgEUxzv6gZ71LFETjbgA+vSphCUpWiE5JK7LSR70ww69sVEJZLGaO3gsi8LQuxZMBUZcYXHvk/lVy3UOAATx1NU9fhkmELWl40M0ThjjkFe4NfW4RQw1P2s3oePV5qkuWJX0u9nvoPPn097OWMlVWXG4U57eRiXJ3MeWxU32gkAMwPrUIEpYGMtgnsa8bH4qnip3itO19juoU50lqQGMglSrDH+yaKvxiTcfOkcovQDqaKyp4DmV3Kxo8Y1olcyFwOhwfelKsGDfdz39aeyvDyTsJ6A9/zoSKaeVTj5CeSeK4lCTdranTKorXvoSCSGeLyHWQMcYwallt3BJbJUc9KnaWzs42eaWNCilmJIzgd65hfHGmz20t6L+ytbBXMSySvne4Gcdu3bvXuRy/mpJz1l0t+p5ylOTbpr3TYZMn5AGXqMdhTjjJA5FUNNvItTjtZtOuhdrJhpGi4SNSCev9K2plZYxvCk4645/OuGeX1IpuasaOuotRRzXh7RxpEl5O91Ld3V1MZpZpABx2UDsAK1yAPmjz1yRTtp5wKlhiJGWHSude1rTu9WXOcUtSCSR3YhydoPQUzPG3AI/l9KhtL63vftZsyzrbTtbSHHAkUAkf8AjwqYBnRjGRvXk5HQYpVKVWNTkqJ8wRlHk5o7Fu2t3Lq6DfCTnJOD7ip7SC10q2MVuFSBWLFF6gsST+ZNc18PfEN1qNo1reLFdSJvdLu1QrC6bsAYPRuuRk9K6W/0+K7sJlUMsjFXDp94MpBFfdYXBPB0Hy6Sa/E8CpWVap72xQup1nYsWKlT3qofnOQuAeakVQMl8Ek0N6DOM18JVqSnNynufSUYRjFKIgUdAopSm7kDnqQP6UEHj6U+MlGDLyVOazW5pJ2V0NXBX19KkC5ODwe2atS28dzGk9qwSRuSmRVKVXQgTBl56nvWtahKm9dUZ06qqabMV1Mbp5gIycgep7VHIWUsWUlC2Tj1Jp3nMmI2wyZyUP8AT0pkLnfhRt+Xce+B/jWdl0NUn1HeTFPC8qzjcckdhTooYmZgz/MzMRg9eORVT5ZCXUBdwzgHA61MsZ28YJ/X/Jqm7EypNrcfJu85cjhkO046/wD16ag2EkdSfyqeGK4ePZKNsI/j6n/9VWJbSOK3x5nBOSf5VaoynFzWyMHVUGoblfS455NYilgXNoysJST0YdMU7VFmuL12Kfux8qYPGPw96G86OAfZnIXy9hKnkc8moBEhVRblnOMn27V01MVz4eFCK2Io0+Wq6jZHIjDO5Wx0HBH4ZpsaPOshjVmEQ+d+y+w96t2xaBZpbqKR41cRqjdx0yKfcTF7M2lsgEe/JKjGADXMoqKvJ6nb7aUnaK07jJoyqQsy7BsGdxBJPqcUxzkAbFyOtJA2wjzVL87ihPGfWpo/sjh5JTN8oHyHjJPasOpom49Cvv2kYZAe/IroNFmE9rKoTaI2wCD1HrWQLiEwsyWYMKnaWHUmtbQFiFqwiY7iAWU9a9rIZ8uKS2POzP36V7F7nvRS96WvvD5sp6pG0tg6opZsjAAz3rEjcI2HyhXgg8Vt6rdm1tMx4EjEDJ7VnG++0YW5SFnB4cCvhs+VJ4htP3j6DLnP2draEbOTknbyfSmhgecjnvnikbO4FVyrDOE7dqQQtjJQRKOm/Az9BXz/ACu1z0lyvQnOFVWf5VP8Q5zTo9Zs4rWW5W4jawRPml2nAOcdMZPNVgTEoQPlfQjpSXunad4hsX0zWbWN4GIbYCVViORnFejl9aEJpS013OXE0na+6L9rcGW1jlkVoo5k3KpxyOx4PHH86hb5w2w47ZFRR20enW8OnxRCKC2QRxIowAvYChxhdqkjtkdq58ZiHUm47JGlCiklLqeaav8ADadZnudL1K4+3M+7zjO8bnJ5BwcevpTdG8Aa3beJNPvJ9YujawSCaQveSSSNg/cweMHv7V6aScke3WkDFuoxzjrXRHOMVGNrr7junNzjaSXrZXLct22MLjAoqouSTnJ449BRXFLEVJO7kzkVGnHSxaiiPl/vyJCecDp+NOWPC4UA47GrKIir0P41W1ElFWXzPJSL947dQVA5B/D0r6angEkns/I8Z123YxYfDSC6vp5buVxdbtw2qGXdjIDemKjtPA3hyDTpLCLSbaW3c7mWZd+5ucEk59TXSbw0BkjG8FNy4/i4yKoaNdXc2lWsuoW5tLmRAzwk5KH04rZ/u7SbsuvT02CVWVRODd/Ig1fVdJ8M2VlFcFbSJmEMMcMRbn+6AorVV4po98wby2AI3jb+lVNV1T7IQk2nTzQMpYzIqsqkHuM5984qGzvbO/nn05T501ukckqMpZVD5K/MRg9K7pqKs0m+r7f1qc6Xu9jR+zLjMY2oeuao6jq1ppl3p1nJHcPLeuUjeKEuikDJ3kfdHPetHynbkgDAxg0+KBVUnaBiro0Um+WFr/12MpzdtzA0WOIy6lBFYmwia4MjF8ATuwBLjHfPHPpVlLU7z5bDOSA3T61qy3MEZAJBbsMVnaheSlZpLJFldIyVQnALds/jXn4vD4bmTcuaZvRnU5WrWRc02C2s7RYbeGOBVJyqDAyTkn8zTERolZoWAbcT65zWBdXmryaNCUSFLxkUOedgfHIzVuxuJRaqsrBpwMHauAx9aK+cpe41p+PqFPAu14li5g3yFkTBPUdM/SqTKV5NaSXcAQIz5I6g9qZMIXAKSnJPfpXh4mlSm+enLVnoUKtSn7sloUNxzj9Ks2pVopDJHvUehwfzqOSFgwzjnvmqsVsupT3Onzw3cCxtHIs4fYJSDnAIOcAjBzjOe9clGm5TSR0VqsXAuEwFQ8JaFvQ/NmmF5ChV2WVepUcU6e1aInO4OevHWq5R92HSpqcydpaF0YwaumWV8txskPljPG8ZBP1qC5ingTKRh1zy8b5yPTimZKg8YPYHpVWG3uv7QlcqjWbqCFODhvatKbi4tNbFOLpyUr6Mlil8xg3lquOCBUrIDC7I4V+2expoOTlju4zk8E1LLAk0DJJHlXTHzdwfSsXvc2m0loZ1lNctrCr9rtRCkeZIg2ZM+o9q1PNdiemw/wAJ9O1U7DTLLTxOLK0SETlS+OTkDANWTwOa3xNWErQpfCvK1+5jRpNtynuCyPExZDitG1mRIZtiiOeUY344/wDrVmeZg8YI9KuBIpmUQtldo6nDbvpWVOcoO8dx16SdrojaSeRFgVjKBxn+9/k1GPMinMTgjAwQfr/9am6nHeWiQzWsanbMBIrEg7O7L6kdcGrE0gmYFCTH1DEfNk9c1M4uKvI0pyT0jsDxqR++HX7si9eTwDUTRReZtafcM7uF/AUrzW9payzXEm1Y+VJP4ZNW7GG2nttzSKWkUYHQfXNTCEpbClNQ3I1leCdLVQDAqbiyjr61LozRrdB1kB6jGetS7riBREsKGLBywIINUtHuo768t54CWRZSuSmARjnGeo9668LCpSrxaVtV+JzVZRqUnc6LzQ2GUfKe9PVgwyCOfWi4RNjAZCjkYqjbxxRz78kluG+lfa1cVUw9WMJaqR4UaUZxbW6Ls0McylZVyCKwbgxfaZIlVSFY4yOnFdAp7jpWRqWnS+a1zAAVAJcd/wAK83P8G6sFUprY68urKEuWbK1tdm3Ro2RWC5wOlMJF1b5zsdZOM/3e4qsr+bPtIYHvkY5zV65t5UIjWNsDk5r5GSmlqj237Pm0ZCqgHA6Z4J5zTxgnjIx0NMK4ADD9aVOATmsTXRkWlRahNc3i6ldxSorb7Zgu1iv90j1HqOuamKrniUZ6YI6e1KFLjGduOhNWIbR5V3p8wAAx0rdKeIlaEdfIxclR1k9CmeTzT0R3YhFY8Z4HSobjUrGx1i1024mX7dcjdFD5TPkZxkkDAHuSK2A4gDKxQN2xwMV1LL6kEpV1yp/j6GU8apaU9StFAZC20crj5TRUzsQu2PAZjzRWkFRpqzjc5pSnJ3vYpXFzJPKWR2jjHAUd/c1BcRvc20sEsrmOVCjc84IwaldQMEbgx7ZBpmQe/fGcYriqYipOftG9Trp04qKikZPh/R5tH8TXt6NQuJLK7gRGtZDuVZFAUSA9vlGCK7DajqBlT9axgvmDbGjE96s2ymNNtyWRj0ycmvWwmYYiS/ex5o7Xen4nDXw1NfA7PsLrdlNeaXd2ttMtvNNA8UU2fuMwwD+GadDpz6dpCQaOsDSxRLHH5pIBwMAsRyaSImW9kZMkKuFx/P8AGtRixtGdTltpwRXu5fXhXUny6L9LHnYiEoNakNrHOIIxdPGZ9o8wxghS3fGecVFNbzkgK+5MnnOCBj9aiXUG+1eXIowByw96T7fKl4ylVaE8Lik81wVSNpXD6pWi7kcnlo8hlTeAMLySc8+tZ3hOPVGhnudSsIbOSSRhHCkm/anbcemfpW1HC8t200nlG3KjaoB3bs9T2xjFW0x/DW9DAwb521Z7dzOpWey36lVopWQxyAGNuq44rMu7NbbYQ+wMcDdzit7PJFU9ahaW13Ku4qc4HWss1yuDoucNZIrCYqUZpN6GLJaxkFjcIxHIGMGlViI8KST/ALuP1oUAnIOacME4r4hyZ9ByoN77c4z26U8sSquhVJBycHFMIyMfw9hQdxHJB46EUKTWxMoJlmzaaYZkjLgHGD3/AC6VPcaaVbfHLNjumdw/XNN0+eOJMO2x89exq/DdRttywDMTj0NfTZbQwlajatL3meTiZ1qc7wWhlm2iuTmNgXXhhtwTQtnInzQ7GBOME1tlRuLYGazda0kajEBFNJBJuDZRivI713zyKnBcxjHHzehE+npI26RlRv4h6/rUSaf9jt9gmaf52YFjnaCc4HtSyJ5NzGtyxm7bgfbvTVBSZdjbU6jJzXz9fEUqcZUYxWv6HoU4Tk1NvYgbimEA9eB61bcqSCRHv7gZxQy2rRH5XicHGVOR+VeXGMXfU9CNVq10UkQZyMkfzqeO3EoJSRUkUFgO+B6GpYrRnwY5Y5B9cH8qbtmW8WF7dBbMhLPk7t3oRjp+Nb0cPOo79Ca2IS0MvT7+5vZHF3bNayxjcsUlwjvtJIDFR0zir3Oec4pLPQrS3v768to0imvGUzSsS7NgYA9gOw6VaEEUiytDK0nlvsYEDBx6U6tByvOmvd/rzZVPExWktyA28VypViuD2fpmlWKKFdpJbttTgH2+lPIwNowM+tMdlRSWIAHJbsB6muNN7GztL0Liao6oFkt4iq/d2jG0elW/PtblYmMQV+isOCtZJyBngj2rM1C7nS+trew0+W4frJLuVVVSe2epHX6V6FDHVtYXTXn/AME5auEp6NaHbxAeWNpJB9apzCSOcmCPL5+UnoPWo9ELyBwoYRKeS3HPoBTNXe7MqrbJIE/iZa+kr4p18FCtyO66L+tjyadJQrOHMacYkVAJSC2OoqRWI6ViRapHboIJpEFwQfKR2AL49M9cVPY3sl0B8pDDg8cV10s2oy5KdneS2sZTwk1ed9EaZVGbcUXd3OOtYFx5kcrzCQkOSNhrdXIHNZurwF2RkXp1xXLneDU6PPCOqNMFW5Z2k9Ch9oRkCLFtJHzH3pqkbSD1z+VTR2jkZI+gqSKzkZtqLtr5NYKvN6Rep7X1mlFbjBE0sgZCMdAtblrEYYuvJqG1sliO49e9WZCc8V9dk+V/VlzzWp4mMxTquy2M7W7lra1kdFQMUOGYcZ7AnsKyvsNzqGhLDq5kilZFLSW7lWz1IBHOO1bV8PMjeNwCpHRhkE0iRl4wJA5HQ8VniqDr1pcur6dkOlU9nFPYpWsZdNkZPHQ5orThSOFNsaFc9yKKKGT0owSqXbCpi5OV47HObgM7j16+ppt5aJdWcsFxPLAJVx+5fY4H17VPH8hBjUtJ13EdPpTQqlt2ASecnmvjYy5GpLc95+9oiawZLK0iggbEUY2jcSxP1Y9TSysbiUHJLHgcUzYMj5h+VWY7mJBzlyP4cAAV1Qqut7tWdkcs4cmsFdk1vZSKPMZ9rnrtHWr1ohW32PwTkVSkv0UAtlV7ZHWraXUTEBH9Pwr6rLp4GnpTl/wTyMTGs9ZIw7y2ltJwXRjGwxu64+tMdmUcnArppFE0Txv91hg1iSadcRMRt81R0Yf4V5eZ5JOlLnw6ujswuPjJctXQZBeeWuyMllA6+lVWkkdixchicgg9KnaN4YNrqwZ25OO3pUYXOSRwc/hXj1aleNqc29Oh1wjSd5ItW19I4RD80nfFa0bHaN4xnqK5e/jnbSbtbCRobt4yI5FALKccYB61Z8F6veat4dtp9WsJtNvxlJYJuuRxkex6ivqsixMp05OrO62t2PJx9JRl7isXL7SyXea2b5252HoazsSrL5bwsJP7o5roVnQSFC6hgccnrUuRuyVG71rbEZNhsXLnpuz62M6eOq0VyyOcn/cKodSrN1J7UBV+UyDKE8jvXRuiSrhlB/CqUlgcloyM9QDXl4vh+dJ81N3R1UsxUlaRmrHZ9Y2LDPAPY04BFO4LKAcgsBwM0x08uZklTax7EcH6UvzNGYQ+1Qex714ntJUanvKzR28inG6e5vqvA2ZIAGDSSKTG4A+bHFc7NcT2MEk8zy+TEu4kZPH4Vr6PqEd/axyxsSrqGUsCpI+h5r7LBZvHGR9nNct9PI8evg3RfNF3MhnZidwIIOMEc0FCMZzyeOODWze2CXDGSPCP1OO9Zc0DxZB3EBsM2OBXy2OyuvhpNtXXc9bD4unUVtmRBY9pyvz+xIpwUEcA5HB704xnrkfX1pYwo3B+MjGTXl9bM7L6XQwgI52nkjBNW453MZh3EgjO48lfpWfqcsqWksllAs10i5WHdtD+27HBpdEnk1HSEupbK50+5VmEkE+Cw54ORweOeK6qFKq4yqQei31/QzqyhopblnLIRkkg9ecU9p7e2s5rqZxHFEpkdsZIUcngdelRk5Byd2BjNQTQpcRvHIoZHBVge4IxWdCv7Oab2HUo88dNzYit7e6t454HWaORQ68cMDyDTLrTbK6sp7S4jCJMjRsPUEYP6GqenslhaxQRErFCojRF7AcAVaS6a4lVGTHOea9+jjcHJrlhaTZ506FaKd3oVtK8PDT9NtrRbmScQIEEkh+ZgOhJ9cYp/wDZUwKdCN3OOwq7fy/Z4EaMhi5xgnp71kkzSXlpcvcXKm3LHYkhCOCMYdeh9R6UsW8BDEONWOu7a+80ovEunzRZD4xvdR0TQZbjRNKe/vnmWKGEYwCTjcfQVvWnnjY0kZjVlBdGIOGI56VQttamku0gmsyiGMv5wcMAwONpHXOOa1knVsjepYDnnpXuUZ4Ssoqm9Y+f4HBONaDfN1MzW9GttaWKK5tUkVGEiuw+6Qeo961YYlghWJAMKMZ9aY84XJySPaqx1KPdgKeabxWEw03KctX/AFoQqVWovdRdI/Ks2fVoLfWoNOuUeNrhN0EhHyyEZyoPqOtXFuA4G3Oaz9Shurye2+y3ZtjDJvb9yr7x6fN0+orsjjaE2k9U/wCuzMnRmjXAA6U5eDx1pkSyBF8wgsByQMZp7EKpLHA61q+SMeZqyROrdkKT61Rt9Us7q8vbS2mD3FmVWdAD8hYblGeh4qjdX8k77YgVjGRnuaS3kMW6UJ+8f7zY5bHHNfPz4jo87hyu3R/8A9FZbNRUm9SXwvpU+k6c0N7ezX0zTSSCaY5YKzFgv0AOK1/esk6pKXjzGEXPJ65/wpx1lQDm1c47q3/1q6459g5at2v5GLy+utLGpRVWDUrWZAS5ib+64orthmGGmrqaMJYerF2cWcxZPetZrHe/ZxIDz5OQp/OpwpDDkHNNGeCW5PelD46sMV+bybbufXKNloSFAD85Y/jU0KpNwltJKvfBwKdp0RuJOV+T1xxWld3QtkAROnQCvUwWXxlTeIxDtFfieZicS1L2VNXZBcWJS380BiFGfL3Hp3FNsI45ll2wMm2QnnPJ9asWWoJO21htb65Bq8T619Fg8JhcQ1VoPTqv8zy61WrTThURDEGVcMQfSpN5HQ1HLGxOVbv0pVzjkV7VNuL5LaI4Za+9cS6jWWFi2AQM7j2rAKRgny2ZyO4OB+Va2qLI8KomcHqPWsl42t1TeOT0XHavkOIZOVayja3U9fLkuTViKRvBClRxjBq00qpIXEmxiu3jnr0qiz4BHbOcNzip4Llo5Y3MQYH+Ejr9K8XD1XTfZdzvrUuZEsULgAunGc5PUn1qc3LQqpUIwzyM9qq3FzNNISW2rnhQOBVZly2XJHOMjnNdTx7oO2Hb9TCOE9p/ENmK7zznj0bipI76OSVVRWJ6E9hWHKrITGw5IyDnORTrSR7QkrGrq3UdK6qWe4iLSm9CZZbBpuJ0F1bR3sBR+vUH0PasDybiFys0ZBHVuxrYtbhJyu0lSRyDzzVoXMLqyM6vjqBzXrYnD4bMkqilZnHSqVcK3G1zmraY3QZbdmZkYq6jsatNFP5q+YNrL0YCthIIeTD+6DHnZxu+tSNArEdQPQGuWnw/fWMzWeYX3iVbWVzxIw6+lXQFK4IBVuvvTJlQKzspOBjaOM1DpySQxlZVZVHIzzivboqdBrD1PeVt+xwS5Z+/HRmXeoYbpoQTsTBBPXBqIbed3JHf0qzcMt3euYyBJnChu9QyW9xHnzLeTPcgbv5V8NiMPOdWcqUW4pvY9+jUjGEVN2ZHkj7mFH0p4kfDAMQCOTTCjqMtFIoH95SKcrK3ofxrlcZ0/iVjovCa01BFeTcVQBV+83YVJDbmRAxwAR+NLK5EMWWwAchR+NW7GfcA8qgAev8AhXTh6dKpNQbt5mFSU4x5kUTDxkA46dakgYQtvfGADnPNaUMayr+lZl+my5YBVC442nP511YjBywSjXhK/Yzo1vbv2ckV7iTz5gyn5AMKDQM7uOO/HapFicrnaQe+RikwFOCAD6Eda8yXPJ80jtUoJWQ1QeGGAR0Iq1pNtGLmeYwoJ5gC0ndscDPrioEYo+GAK9WOORVzTCouCST0IBPcV6GVT5cRFc1k9GcmL1pvQoeKddTRNKe4Fpc3jZVBDax75HYnAAHpz1pbWV5reGSSNoJHUM0RIJQ4yRkcce1WL2NPPX5BuBzu9KSGAyy/MyooPXrTxlaeIq+za1vuTRhGnDmC3uTFkMm9Ovy1pWl5DcYVTtcdFYYP/wBes688vcI4QDjqw6U2zQvPEACfmBOB0FdWXY6vQrxw8XzRvYyxFCnOm6j0Zuc98VV1Ritm+DgnAzV1h6Gq1/D5tq4A5HNfWZmpSwlRQ3seThbKtG5hoCcAH2qQ7oioflff0pqcHBHINazwx3NpGchX7H+hr4HCYN4qM+V+8tvM+ir1/ZSV1ozHI2dOlIRjkU+WNo2KuCCOxpqc9OeK43FxfLJanQnpzIZgcZHNFSMhC9cqeM0UPQatLWwq2dtMx2SYwO4zV2O0sIwDJh29WPX8KzJFkhbD5w3BFULW0u4JZhPfNNAX3Qq8YBjBJyuR1Hp9K9WjiXh781Nc3mmcE6XtbWm7HTS3CRRYiwFHoKoy3O98lQc1m2dzPd311am3n8uDbmd02xuSM4Unrgde1W9pQ/cwBSx+LxNb3ai5V26BQoUYaxabJIonMwYL1Nbcyvs+XAOOaxo57osohUH8KtXNlFcOkszzCYAAqkhC/lXq5JKlGE0+ZXW/6I4scpOSd0y0tysagTttOcVYBB6EHPpWXFZRSanLeuWNw8SwkFshVUkjA9fmNTz28kMWbUAtkcFscV7OHxFVL3dY+e5wzpxe+jL3s361kahE63LzTBmXPyYHAA9aZqt3qUUtotnZxTwO+J5Gm2GJexAwd30yK0Ibl0RVZQQOCazx7pYuKp1NE1dP/gDoc1J80TDVlEodsMM8j1qzqMokukZR+78shQO3WtMm0lkBaMKRyccZNSmK2cAbBivHhkrcJRhUTTO6WO95ScTn26KR/F0xTsZbuVHNaVxpyPgxOoA6Z7fSmLpqlSEl+Yjoxrz55PiVKyX4nRHG03HUpnLElsevSkKk4J5qV4preXLx5OOCOlMjDlNwRimMk9MCvPnh6sZcsou50xqxtdPQdHsUnAPIwadp9xEUMEcYiePCkHuB3z3olt5IwhkjKBzhcsOT2FCWU25mKFcDBJ4NdtCOLoOygzCboVE7s1AY7iP/AEZsMnVe4qa3jcIDKfm9qqWEIiffMQuB8oz1q6/76ImNhyODX2GBXNH6xUXv22uePW0fJHYZO3lwtg8jmmWcxkchjxjIGKy3ScTL5zfIeDzkVqWtrHbru53HHOa4sNjK2LxXNblitzapRhSpWvdsf9jg85ZcfOCT9atFyOScfXisnUb2RWlgRQGwMEj9c1jskzZ3SFzjHzHNZ4rOaOEm6dGCffoa4fAyrrmnKx1pJPUA+ves2/gV1zFGpkHPPUiseCe8hOYCSVGQM9af4f1e+1tLl7/TH00Rvsi8x13yDu2ATgenNZyxscxw8k4Wa81+A3Q+rVEua4m12YMMDbwO2KmiYAbnLcdsUXKESOAh2nuWqNYmZMAYAr5Jpwlbqj2tJxVzQtZmkgePChx0Yd6pi2zuwDuHJ96dZDZcAE8EcqOp/Gpb/Q2m0vUoba8mgnvFZVm3EtDkYyvpj+de/g8LPMqaUn8Oh5lapHCydupXllcpsLk9uTVi0uFVGDheo+93qG+spbN0CiSS3CAeZnLZ6c1XYgoWznFeXUhWwNa0tGdsfZ4indE90qmUlQoB64ptuzLKmM4JxjFX7TT8hHLfKwyQallsD1ViCpBGK7oZTiqlsRbfU5ZYylH92Z8+FkYnvzwafEkcoIL7WIz9aJ7eRN7D51zk44xUO1kYFc+1cUlLD1f3kbrszZctSHusmOny4ysieXjqBzTrS9EcmyOLbH/Ex6/WpIpv+enQ9wKS1thOxYMvl56/0r0aUU6kHgtJPf8Arsc8m+VqtquhoNMBtI+YN3FSjpUKRII0Qnkehp+5VIQcY9K+whKVrze55DS+yZd5bGGbI/1TH5fb2qzFCraeDGQjgkhqtuVMbK2CKzp7gRAxjgDke9fO4nD4fL5Tm9YzWx6NOpUxPLHqiJle4UqxBlTg+jCmxWZJzL8oHYHrT7E7Y5JGOT1qu0zMXycMc4IrxKkqcYwq1FeTX/A+87oqbvCL0Qy5iCPtDk8cEdKKa0kjoFkAOKK4JNNtx0R3001GzLF9ax6la+TOZ413Bj5Mhjbg9Nw5x7VYkkEQjVbfcx4HfH1pkpJGUJB96Rmn8k+W0bS8YDZAxnv+FfTQrt/u727PQ8BwS9//ADHRzrhjJID9Dx+FVbXUGuJLlJbCaEROVVpCuJF/vDB6fWr/AJFsVX5VZByKW6toZozEANjgq656g10ey5YPVP8A4clzu1oNhmWSEvCylQM5U1nzi6u7q0NtcNbeRLvlXaGEyYIKH06g5HpWjp1nb6darb2yLHCihVUdh6UxEMM/CnyyMk46Vm6U4ThKMvX0/r/gBzKSaaKuvW93caNf2+lzi31CaBkglYHEbEYDfhU9iWgtbe2lkeWaONQZDzuIGCc1Knmea5YgxkcCqOo3o0yAzSwyPAXVcwruK57kdcCuylP2i5IR1u/V7GLjZ3bLiTq80kBR12AfMV+U1BdMf3nlKGMQDYPOev8ACOalgvI5LkWxWRmAzvK8H2z61j60ItF1SXXJJTHbm2KXIRC5baRsPHIIy34GtXTTdoq/5/120Hfl1Zh2Wn3+naxeeIfFeriERjyIYo5CsDRkDGIyCd+7tkn+VdBeakxtLaC1u7a21S9Tdapchvm7nKDB4H0rVtriO9t4pfLLowDqW7jsazNd17TdM1Kwg1J2iuLxzFA3lMwJ44LAEL171nWqU5Wag+fsttF2/MmClG6ctO7/AKt6Elnq1sXls5b62lv7SNWu1jfHlEjqRnKjgnmp7PU4ru38+1k8yEsVVypAPuMjke9UNJ0G5ttc1W+ubuKS2u2Hl28dusYXAxl26u3bJPTtW0Y08soDt4wCO1cVR1E7xl21+WvTv/TNocrWqGrcMgLFmlABG3Oc1y3hHzIfE+uC+urp7i4k+0C2Y5iiiOBGqj1AU5x3Jrc0TTprC1MVzf3V8xbIkuNu4D0+UDI47+tJfWOqT6hby2N9Fa26MDIhgDNIB1XJ6d62wleqnKDaafW3+aHOMGr2t/Xky/fWsGpS2rXCea9pMJ41JxtcAgN/48agvLfULnWbaSK/MFjEN0lukQJlbn7zHoOnAFayKVUf4UMOMDg+1eovdV9zk66HMXfi7SYtQgsI5HuLuW8+wlI0Z9j4BO7AwAARk+9dHFGmP3MijtgVVtbKCzV1tIUi3SPKxUfedjlifcmsl4dP8PXFxqeoaxPFHOSCLu6/dKSc/KDwOmOO1cs69Ln5acfv6+ltjVQk1r+H63Lupy6nFeRQ2Wmx3Vs4DSTNcCMIc8jGCTxzUup219PptzFp86217JERDK43rG54zjvjrSJd6g+reVHZJ/ZvlB/tRm5Zj/CEx0981edmxyeacqtGnZ+z1++/rr+FkJRlK/vf8ApT2PnaXHZ3dxK8uxVeeM+WzEYyRjpmq/2EJY/ZUklA2bBLvzIPfcc5PvWiQW9zWTf6ZPPqEN5DfXMTQoQtuHxC59XGMn868XFS9tLmtZb7HbR9xWuWYFS3SO3gQCNAMliSQPqep61XXUl1KGdNGhH2q3mEUjXkLogHU4zjdkdCOK0IwSq7/v4G7A4zVqztoYySufmOeTmt8tg/aa637kYmXukFzbwlRthlZj/EueKhOmzbTsmz7OuM1tM+0fLSeZnpXqVcpwtR+/v/AF2OeGLqwVolC006OJ98rliOBRqd7HbyWluVlJupPKUxoSF4JySOnA71cZS/J4+lVpXMfUtn09a0g4YKnywjZf16kPmrSu3qWWdQmxhlDxzVKTSVaQtBKEiJyUI6fSliPyAvuT8OlTCUBSRIGA9OazqOlidcRFMqPPT0psnd0jUDKgAY61WluSTiIg+vPH51jSW7xa5NqF1ezPbPGIorYcIhzkt7k8fStaNg3KrxjqRSqY2VWXs6bstNgjRSXNJajmkLEK+1c9qj2xFslQD/ADqOa4jEvlyBumS54A+pp75JxjgjsKxqtT+JX9UaRVttBskVuV2jI9MU+FYIYgqnAPPNUbmO5itrmSB1eXYTGJTtUNjjJ9M0/RZpG022fUo447xowZVjfegbvtPGRWVG0Z87UY+ZU1eNk2xupz3MVq0umWoubgMFEZkCA5PUnHbrU6TSLEHmjYMQAVHzc/4e9WTImf3ZHTpSBieufwraTT0i7+hMfNGV4e1n+047xzb3EBgupLYrMMbihxuHse1atzZxXChgdjDuKq3twLeGRlXcwIG0dyelTxPItonmABiOVHaplyunKNaN4ra5STUk4vUpSg2wIViw9R3qJ4nCeYFJjI5x/DU2HuGPB47dajlYoNgfpwV/Cvk507Rc5J8r29T1YSbkop69SvwTjOPrRSEBYmJkVEX5mLdMUVypN7HW520P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tissue gram stain of muscle biopsy (x400) from a patient with gas gangrene shows numerous Gram positive bacilli. Clostridium perfringens grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17729=[""].join("\n");
var outline_f17_20_17729=null;
var title_f17_20_17730="Torsion with salvageable ovary";
var content_f17_20_17730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian and tubal torsion demonstrating marked vascular engorgement as well as increased size and distension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomy was restored and both structures were salvaged despite non-viable appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17730=[""].join("\n");
var outline_f17_20_17730=null;
var title_f17_20_17731="BAL in alveolar proteinosis with eosinophilic bodies";
var content_f17_20_17731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PAS stain of bronchoalveolar lavage fluid in pulmonary alveolar proteinosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopy of bronchoalveolar lavage fluid from a patient with pulmonary alveolar proteinosis shows large acellular eosinophilic bodies in a background of eosinophilic granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17731=[""].join("\n");
var outline_f17_20_17731=null;
var title_f17_20_17732="Small plaque parapsoriasis 2";
var content_f17_20_17732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small, slightly erythematous or brown/yellowish patches and thin plaques with little scaling in a patient with small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17732=[""].join("\n");
var outline_f17_20_17732=null;
var title_f17_20_17733="Polymyxin B: Drug information";
var content_f17_20_17733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polymyxin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/31/15860?source=see_link\">",
"    see \"Polymyxin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25012?source=see_link\">",
"    see \"Polymyxin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Irrigation;",
"     </li>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear canal infections (external):",
"     </b>",
"     Otic (in combination with other drugs): Instill 1-2 drops, 3-4 times/day; should be used sparingly to avoid accumulation of excess debris.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     25,000-30,000 units/kg/day divided every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     15,000-25,000 units/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrathecal:",
"     </i>",
"     50,000 units/day for 3-4 days, then every other day for at least 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Total daily dose should not exceed 2,000,000 units/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder irrigation (in combination with 57 mg neomycin sulfate):",
"     </b>",
"     Continuous irrigant or rinse in the urinary bladder for up to 10 days using 20 mg (equal to 200,000 units) added to 1 L of normal saline; usually no more than 1 L of irrigant is used per day unless urine flow rate is high; administration rate is adjusted to patient's urine output.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical irrigation or topical solution:",
"     </b>",
"     500,000 units/L of normal saline; topical irrigation should not exceed 2 million units/day in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ocular infections:",
"     </b>",
"     Ophthalmic: A concentration of 0.1% to 0.25% is administered as 1-3 drops every hour, then increasing the interval as response indicates to 1-2 drops 4-6 times/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25012?source=see_link\">",
"      see \"Polymyxin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear canal infections (external):",
"     </b>",
"     Otic (in combination with other drugs): 1-2 drops, 3-4 times/day; should be used sparingly to avoid accumulation of excess debris",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic infections:",
"     </b>",
"     Infants &lt;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     Up to 40,000 units/kg/day divided every 6 hours (not routinely recommended due to pain at injection sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Up to 40,000 units/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrathecal:",
"     </i>",
"     20,000 units/day for 3-4 days, then 25,000 units every other day for at least 2 weeks after CSF cultures are negative and CSF (glucose) has returned to within normal limits",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;2 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F211310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: Administer 75% to 100% of normal daily dose given in divided doses every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-20 mL/minute: Administer 50% of normal daily dose given in divided doses every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: Administer 15% of normal daily dose given in divided doses every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding [micronized]: 50 million units, 100 million units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dissolve 500,000 units in 300-500 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W for continuous I.V. drip; dissolve 500,000 units in 2 mL water for injection, saline, or 1% procaine solution for I.M. injection; dissolve 500,000 units in 10 mL physiologic solution for intrathecal administration",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     Monitor I.V. site closely; extravasation may cause serious injury with possible necrosis and tissue sloughing. Rotate infusion site frequently.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F211333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cloxacillin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute infections caused by susceptible strains of",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ; used occasionally for gut decontamination; parenteral use of polymyxin B has mainly been replaced by less toxic antibiotics, reserved for life-threatening infections caused by organisms resistant to the preferred drugs (eg, pseudomonal meningitis - intrathecal administration)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Facial flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity (irritability, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurred vision); dizziness, drug fever, meningeal irritation with intrathecal administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticarial rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hyponatremia, hypokalemia, hypochloremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuromuscular blockade, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polymyxin B or any component of the formulation; concurrent use of neuromuscular blockers",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause nephrotoxicity; avoid concurrent or sequential use of other nephrotoxic drugs (eg, aminoglycosides).",
"     </b>",
"     Usual risk factors include pre-existing renal impairment, advanced age and dehydration. Polymyxin B-induced nephrotoxicity may be manifested by albuminuria, cellular casts, and azotemia; discontinue therapy with decreasing urinary output and increasing BUN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neurotoxicity, which can also result in respiratory paralysis from neuromuscular blockade especially when the drug is given soon after anesthesia or muscle relaxants. Avoid concurrent or sequential use of other neurotoxic drugs.",
"     </b>",
"     Neurotoxic reactions are usually associated with high serum levels, often in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with impaired renal function; modify dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Safety in pregnant women not established.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.M./I.T. administration:",
"     <b>",
"      [U.S. Boxed Warning]:  Intramuscular/intrathecal administration only to hospitalized patients.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: Polymyxin B sulfate is most toxic when given parenterally; avoid parenteral use whenever possible.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     : Safety in pregnant women has not been established. A teratogenic potential has not been identified for polymyxin B, but very limited data is available. Based on the relative toxicity compared to other antibiotics, systemic use in pregnancy cannot be recommended. Due to limited absorption through the maternal skin, limited fetal exposure would be expected after topical polymyxin use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7306030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if polymyxin B is excreted in human milk. Due to the limited oral bioavailability, toxicity in a breastfed infant may be unlikely. Infant exposure would be even less after topical use due to the limited maternal skin absorption. Nondose-related effects could include modification of the bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Polymyxin B Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500000 unit (1): $12.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurologic symptoms and signs of superinfection; renal function (decreasing urine output and increasing BUN may require discontinuance of therapy)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F211288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentrations &gt;5 mcg/mL are toxic in adults",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerosporin (IN);",
"     </li>",
"     <li>",
"      Alosol (MX);",
"     </li>",
"     <li>",
"      Biodexan Ofteno (MX);",
"     </li>",
"     <li>",
"      Cortisporin Otico (MX);",
"     </li>",
"     <li>",
"      Dexsul (MX);",
"     </li>",
"     <li>",
"      Glubacida (MX);",
"     </li>",
"     <li>",
"      Isopto-Biotic (SE);",
"     </li>",
"     <li>",
"      Maxitrol (MX);",
"     </li>",
"     <li>",
"      Neobacigrin (MX);",
"     </li>",
"     <li>",
"      Neosporin (MX);",
"     </li>",
"     <li>",
"      Polixin (MX);",
"     </li>",
"     <li>",
"      Polymyxin B Pfizer (DE);",
"     </li>",
"     <li>",
"      Polymyxine B FNA (NL);",
"     </li>",
"     <li>",
"      Septilisin (MX);",
"     </li>",
"     <li>",
"      Synalar (MX);",
"     </li>",
"     <li>",
"      Syntex (MX);",
"     </li>",
"     <li>",
"      Tribiot (MX);",
"     </li>",
"     <li>",
"      Trioft&iacute;n (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to phospholipids, alters permeability, and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from peritoneum; minimal from GI tract (except in neonates) from mucous membranes or intact skin. Clinically insignificant amounts are absorbed following irrigation of an intact urinary bladder; systemic absorption may occur from a denuded bladder. Small amounts are systemically absorbed following ophthalmic installation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Minimal into CSF; V",
"     <sub>",
"      d",
"     </sub>",
"     : 71-194 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 79% to 92% (critically ill patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 6 hours; 2-3 days with anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Evans ME, Feola DJ, and Rapp RP, &ldquo;Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(9):960-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/20/17733/abstract-text/10492501/pubmed\" id=\"10492501\" target=\"_blank\">",
"        10492501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horton J and Pankey GA, &ldquo;Polymyxin B, Colistin, and Sodium Colistimethate,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1982, 66(1):135-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/20/17733/abstract-text/6278236/pubmed\" id=\"6278236\" target=\"_blank\">",
"        6278236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zavascki AP, Goldani LZ, Cao G, et al, &ldquo;Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 47(10):1298-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/20/17733/abstract-text/18840079/pubmed\" id=\"18840079\" target=\"_blank\">",
"        18840079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9790 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17733=[""].join("\n");
var outline_f17_20_17733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709216\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211327\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211308\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211321\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211309\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211310\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211287\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211272\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211333\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977966\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211325\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211293\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211276\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299903\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211281\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211283\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211295\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211314\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306030\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323703\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211285\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211288\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539915\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211275\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211292\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/31/15860?source=related_link\">",
"      Polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25012?source=related_link\">",
"      Polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_20_17734="Portable monitoring in obstructive sleep apnea in adults";
var content_f17_20_17734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Portable monitoring in obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17734/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17734/contributors\">",
"     Nancy Collop, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17734/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17734/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17734/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17734/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/20/17734/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable monitoring (PM) is a diagnostic test for obstructive sleep apnea (OSA), a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. It has evolved as an alternative to overnight, attended, in-laboratory polysomnography (PSG) in selected patients.",
"   </p>",
"   <p>",
"    Advantages of PM include its convenience (it can be performed in the patient's home or in a hospital room) and its lower costs (PM devices are less costly than complete polysomnography systems and the attendance of a technologist is not required). However, a disadvantage is that fewer physiologic variables are measured during PM than PSG, which can lead to misinterpretation of the results. Other advantages and disadvantages are listed in the figure (",
"    <a class=\"graphic graphic_table graphicRef67817 \" href=\"UTD.htm?18/52/19275\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The United States Centers for Medicare and Medicaid Services (CMS) have released guidelines that state that results from PM can be used to support a prescription for positive airway pressure therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/1\">",
"     1",
"    </a>",
"    ]. The American Academy of Sleep Medicine (AASM) has also released clinical practice guidelines to guide clinicians in the use of PM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of PM in the diagnostic evaluation of suspected OSA is reviewed here. The diagnostic approach to a patient with suspected OSA is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF MONITORING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four types of sleep study monitoring devices have been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type 1 devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 monitoring devices are used for in-laboratory, technician-attended, overnight polysomnography (PSG). These devices are not used for PM and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type 2 devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 monitoring devices can record the same variables as type 1 devices. The major difference from type 1 devices is that they can be used outside of the sleep laboratory and a technologist is not present during the recording.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type 3 devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 monitoring devices typically measure four physiologic variables, including two respiratory variables (eg, respiratory movement and airflow), a cardiac variable (eg, heart rate or an electrocardiogram), and arterial oxyhemoglobin saturation via pulse oximetry. Some devices have additional signals that can detect snoring, determine body position, or detect movement. Sleep variables (eg, sleep stages, sleep continuity) are typically not measured by a type 3 device, although some newer devices have methods for estimating sleep. A technologist is not present during the recording.",
"   </p>",
"   <p>",
"    Recordings from a typical type 3 portable monitoring device are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef77569 \" href=\"UTD.htm?10/5/10326\">",
"     figure 1",
"    </a>",
"    ). In this example, respiratory effort is detected by a chest wall impedance monitor, airflow is detected by a heat-sensitive thermistor at the nose and mouth, and oxyhemoglobin saturation is measured by a pulse oximeter. The heart rate is also recorded. Measurement of these variables is generally sufficient to detect most apneas (obstructive, central, mixed) and hypopneas.",
"   </p>",
"   <p>",
"    Type 3 devices have important limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 3 devices do not typically detect arousals from sleep because they do not include electroencephalography (EEG). As a result, respiratory effort related arousals (RERAs) cannot be detected and hypopneas characterized by arousals may remain undetected. The inability to detect RERAs may lead to underestimation of the respiratory disturbance index (RDI) and under-recognition of upper airway resistance syndrome (UARS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H8#H8\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory effort related arousals'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H19#H19\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Upper airways resistance syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The apnea hypopnea index (AHI) is calculated by dividing the number of apneas and hypopneas by the study duration when determined by a type 3 device. In contrast, the AHI is calculated by dividing the number of apneas and hypopneas by the duration of sleep in hours when derived from conventional PSG. The effect is that an AHI derived by PM is usually lower than an AHI derived by PSG. This decreases the diagnostic sensitivity of type 3 devices, compared to type 1 and 2 devices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H10#H10\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Summary measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many type 3 devices do not record position, so they may not be able to detect when the patient is lying in the supine or lateral decubitus position. Thus, OSA that develops or worsens in the supine position may not be detected.",
"     </li>",
"     <li>",
"      Type 3 devices cannot distinguish rapid eye movement (REM) sleep from non-REM (NREM) sleep because they do not monitor EEG. As a result, the interpreting clinician cannot be certain that a period of REM sleep was captured during the study. This is an important limitation because severe perturbations are most common during REM sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type 4 devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 4 monitoring devices are defined differently by different organizations. The American Academy of Sleep Medicine (AASM) defines type 4 monitoring devices as devices that record one or two variables (eg, arterial oxyhemoglobin saturation and airflow) and can be used without a technician. These devices are called continuous single or dual bioparameter devices. In contrast, the United States Centers for Medicare and Medicaid Services (CMS) guidelines include devices that measure three variables as type 4 monitoring devices. A technologist is not present during the recording.",
"   </p>",
"   <p>",
"    Type 4 devices that record one or two variables provide limited information. Pulse oximetry and airflow are the physiological variables that are most commonly measured. As a result, derived information typically includes the frequency of apneas, frequency of hypopneas, AHI, baseline oxyhemoglobin saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ), mean SpO",
"    <sub>",
"     2",
"    </sub>",
"    , frequency of oxyhemoglobin desaturation, duration of oxyhemoglobin desaturation, degree of oxyhemoglobin desaturation, and nadirs of SpO",
"    <sub>",
"     2",
"    </sub>",
"    . All of the limitations of type 3 devices described above also apply to type 4 devices.",
"   </p>",
"   <p>",
"    A novel type 4 device measures arterial tonometry, oximetry, snoring, and body position. It uses an automated algorithm to detect breathing events based upon peripheral arterial tone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulse oximetry alone is also considered a type 4 device, which is discussed further below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pulse oximetry'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3478043\">",
"    <span class=\"h2\">",
"     New classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new classification scheme for PM devices has been proposed, the SCOPER categorization system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/7\">",
"     7",
"    </a>",
"    ]. The acronym SCOPER stands for",
"    <strong>",
"     S",
"    </strong>",
"    leep,",
"    <strong>",
"     C",
"    </strong>",
"    ardiovascular,",
"    <strong>",
"     O",
"    </strong>",
"    ximetry,",
"    <strong>",
"     P",
"    </strong>",
"    osition,",
"    <strong>",
"     E",
"    </strong>",
"    ffort, and",
"    <strong>",
"     R",
"    </strong>",
"    espiration. The SCOPER categorization system provides a more detailed description of the type of physiologic parameters that are being measured and how they are being measured than traditional classification schemes. The system is described in detail in the table (",
"    <a class=\"graphic graphic_table graphicRef85891 \" href=\"UTD.htm?8/13/8413\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example of how the SCOPER system is applied, consider a device that measures actigraphy, derives the pulse rate from the oximetry, measures oximetry with an adequate sampling rate, uses a mercury position sensor, measures effort via a piezo belt, and measures respiration via a thermocouple; this device would have a SCOPER designation of S",
"    <sub>",
"     3",
"    </sub>",
"    C",
"    <sub>",
"     4",
"    </sub>",
"    O",
"    <sub>",
"     1",
"    </sub>",
"    P",
"    <sub>",
"     2",
"    </sub>",
"    E",
"    <sub>",
"     4",
"    </sub>",
"    R",
"    <sub>",
"     3",
"    </sub>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for PM include the diagnostic evaluation of suspected OSA and titration of positive airway pressure therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many PM devices have been validated against standard PSG, typically by testing the same patient with both modalities in the sleep laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. A wide range of diagnostic characteristics have been reported using PM, but the sensitivity and specificity seem to be high in populations considered by sleep specialists to be at high risk of OSA on the basis of clinical symptoms, assuming there are no comorbid medical disorders or sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We endorse the most recent clinical practice guidelines from the American Academy of Sleep Medicine (AASM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PM for diagnostic evaluation of suspected OSA should be performed only in conjunction with a comprehensive sleep evaluation, preferably by a sleep medicine specialist.",
"     </li>",
"     <li>",
"      PM may be used as an alternative to PSG for the diagnosis of OSA in patients with a high pre-test probability of moderate to severe OSA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PM should not be used in patients who have comorbid medical conditions that predispose to sleep related breathing disorders or in whom another sleep disorder is suspected. As an example, PM should not be used in patients with heart failure because they are predisposed to Cheyne-Stokes breathing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"       \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An experienced sleep technician, sleep technologist, or appropriately trained provider must apply the PM sensors or directly educate the patient about the correct application of sensors. In addition, there should be methodology in place to monitor the quality of recordings.",
"     </li>",
"     <li>",
"      PM devices must be capable of displaying the raw data for review by the clinician, in order to allow assessment of the quality of the data.",
"     </li>",
"     <li>",
"      All patients undergoing PM should receive a follow-up visit with an appropriately trained provider to discuss the results of the test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CMS guidelines do not make any specific recommendations about which type of PM device should be used, nor do they specify the appropriate population to undergo PM. However, they do indicate that positive airway pressure therapy prescriptions will be covered by Medicare and Medicaid only if OSA is diagnosed using a type 1, 2, or 3 device [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, a Type 4 device that measures at least three variables is acceptable.",
"   </p>",
"   <p>",
"    A technology evaluation reviewed the literature for evidence regarding which devices are most appropriate for the diagnostic evaluation of suspected OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/7\">",
"     7",
"    </a>",
"    ]. The evaluation concluded that all devices must have an oximeter and the most robust evidence support the use of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Devices with a thermal sensor and two effort belts",
"     </li>",
"     <li>",
"      Devices with a nasal sensor and two effort belts",
"     </li>",
"     <li>",
"      Devices utilizing peripheral arterial tonometry",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;PM has important limitations that should be routinely considered by the clinician who is interpreting the results of the study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 3 and type 4 devices often underestimate the AHI (described above), increasing the likelihood of a false-negative result. As a result, the pretest clinical suspicion for OSA and the results of PM studies should always be considered together. Additional testing is indicated whenever there is a reasonable clinical suspicion for OSA, but the PM study is negative.",
"     </li>",
"     <li>",
"      Type 4 devices that record only one or two physiologic variables cannot distinguish obstructive and central events, in part because respiratory effort is not measured. Patients at risk for central apneas, hypopneas, or hypoventilation should not be tested with such devices.",
"     </li>",
"     <li>",
"      Different manufacturers use different sensors and potentially different algorithms to identify respiratory events. Many devices do not allow the raw data to be viewed by the provider who ordered the test because the scoring algorithm is proprietary. This is problematic according to numerous studies that showed that manual scoring or manual editing of automated scoring improves diagnostic accuracy compared to automated scoring alone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/12-17\">",
"       12-17",
"      </a>",
"      ]. Clinical practice guidelines recommend manual scoring or manual editing of automated scoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of portable monitoring in determining the initial level of positive airway pressure therapy is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=see_link&amp;anchor=H10#H10\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\", section on 'Determining the amount of positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reassessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;PM can be used to assess the adequacy of the prescribed therapy within a patient's usual environment and to guide adjustment of the therapy. The approach is similar to that for diagnosis and titration, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULSE OXIMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry is a widely accepted and important component of both polysomnography (PSG) and PM. However, when it is measured alone or with only one other variable, it is not recommended for the diagnostic evaluation of suspected OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/1,2,18\">",
"     1,2,18",
"    </a>",
"    ]. In this section, we briefly describe the reason that overnight oximetry alone is not considered an acceptable diagnostic modality.",
"   </p>",
"   <p>",
"    The characteristics of overnight pulse oximetry alone as a diagnostic test are highly dependent upon whether the criteria used to define a positive test are quantitative or qualitative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overnight pulse oximetry tends to have a high specificity but a low sensitivity when quantitative criteria are used [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. As an example, a study of 200 patients with suspected OSA compared overnight pulse oximetry versus polysomnography [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/20\">",
"       20",
"      </a>",
"      ]. Positive overnight pulse oximetry was defined as a decrease in the oxyhemoglobin saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      ) of 4 percent or greater from baseline, to a value 90 percent or lower. Overnight pulse oximetry had a sensitivity of 41 percent and a specificity of 97 percent.",
"     </li>",
"     <li>",
"      In contrast, overnight pulse oximetry tends to have a high sensitivity but a low specificity when qualitative criteria are used [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17734/abstract/10\">",
"       10",
"      </a>",
"      ]. Qualitative criteria emphasize pattern recognition. The overnight pulse oximetry strip is printed and visually analyzed for a pattern of multiple, short-duration fluctuations of the SpO",
"      <sub>",
"       2",
"      </sub>",
"      . No specific level of desaturation is required for a positive study. As an example, a study of 240 patients with suspected OSA compared overnight pulse oximetry versus polysomnography. Positive overnight pulse oximetry was defined as greater than 10 fluctuations of SpO",
"      <sub>",
"       2",
"      </sub>",
"      per hour of sleep. The sensitivity and specificity of overnight pulse oximetry were 98 and 48 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overnight pulse oximetry alone can be either a sensitive or a specific test for OSA, but not both. As a result, either false-positive or false-negative tests will be common, depending on the criteria chosen to define a positive test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"       \"Patient information: What is a sleep study? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Portable monitoring (PM) is an acceptable approach to the diagnostic evaluation of suspected obstructive sleep apnea (OSA). However, it should only be used for the diagnostic evaluation of suspected OSA in patients with a high pre-test probability of having moderate to severe OSA and no comorbid medical or sleep disorders. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PM can also be used to guide the titration of positive airway pressure therapy if the chosen mode of positive airway pressure is either continuous positive airway pressure (CPAP) or autotitrating positive airway pressure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Titration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several types of PM devices. Type 3 and 4 devices have highly variable diagnostic performance and most do not include a conventional measure of sleep, which has many drawbacks. This was supported by a technology evaluation that found that some devices clearly perform better than others. The SCOPER categorization system provides a more detailed description of individual devices than traditional categorization schemes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of monitoring devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulse oximetry is a widely accepted and important component of both polysomnography and PM. However, it should NOT be used alone for the diagnostic evaluation of suspected OSA. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulse oximetry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Department of Health and Human Services, Center for Medicare and Medicaid Services. Decision Memo for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA). CAG#0093R. March 13, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/2\">",
"      Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007; 3:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/3\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/4\">",
"      Ferber R, Millman R, Coppola M, et al. Portable recording in the assessment of obstructive sleep apnea. ASDA standards of practice. Sleep 1994; 17:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/5\">",
"      Choi JH, Kim EJ, Kim YS, et al. Validation study of portable device for the diagnosis of obstructive sleep apnea according to the new AASM scoring criteria: Watch-PAT 100. Acta Otolaryngol 2010; 130:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/6\">",
"      Pang KP, Gourin CG, Terris DJ. A comparison of polysomnography and the WatchPAT in the diagnosis of obstructive sleep apnea. Otolaryngol Head Neck Surg 2007; 137:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/7\">",
"      Collop NA, Tracy SL, Kapur V, et al. Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. J Clin Sleep Med 2011; 7:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/8\">",
"      Man GC, Kang BV. Validation of a portable sleep apnea monitoring device. Chest 1995; 108:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/9\">",
"      White DP, Gibb TJ, Wall JM, Westbrook PR. Assessment of accuracy and analysis time of a novel device to monitor sleep and breathing in the home. Sleep 1995; 18:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/10\">",
"      S&eacute;ri&egrave;s F, Marc I, Cormier Y, La Forge J. Utility of nocturnal home oximetry for case finding in patients with suspected sleep apnea hypopnea syndrome. Ann Intern Med 1993; 119:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/11\">",
"      Tonelli de Oliveira AC, Martinez D, Vasconcelos LF, et al. Diagnosis of obstructive sleep apnea syndrome and its outcomes with home portable monitoring. Chest 2009; 135:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/12\">",
"      Ancoli-Israel S, Mason W, Coy TV, et al. Evaluation of sleep disordered breathing with unattended recording: the Nightwatch System. J Med Eng Technol 1997; 21:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/13\">",
"      Cirignotta F, Mondini S, Gerardi R, et al. Unreliability of automatic scoring of MESAM 4 in assessing patients with complicated obstructive sleep apnea syndrome. Chest 2001; 119:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/14\">",
"      Dingli K, Coleman EL, Vennelle M, et al. Evaluation of a portable device for diagnosing the sleep apnoea/hypopnoea syndrome. Eur Respir J 2003; 21:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/15\">",
"      &Oslash;verland B, Bruskeland G, Akre H, Skatvedt O. Evaluation of a portable recording device (Reggie) with actimeter and nasopharyngeal/esophagus catheter incorporated. Respiration 2005; 72:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/16\">",
"      Yin M, Miyazaki S, Ishikawa K. Evaluation of type 3 portable monitoring in unattended home setting for suspected sleep apnea: factors that may affect its accuracy. Otolaryngol Head Neck Surg 2006; 134:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/17\">",
"      Yin M, Miyazaki S, Itasaka Y, et al. A preliminary study on application of portable monitoring for diagnosis of obstructive sleep apnea. Auris Nasus Larynx 2005; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/18\">",
"      Chesson AL Jr, Berry RB, Pack A, et al. Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. Sleep 2003; 26:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/19\">",
"      Williams AJ, Yu G, Santiago S, Stein M. Screening for sleep apnea using pulse oximetry and a clinical score. Chest 1991; 100:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/20\">",
"      Douglas NJ, Thomas S, Jan MA. Clinical value of polysomnography. Lancet 1992; 339:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17734/abstract/21\">",
"      Gyulay S, Olson LG, Hensley MJ, et al. A comparison of clinical assessment and home oximetry in the diagnosis of obstructive sleep apnea. Am Rev Respir Dis 1993; 147:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7694 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17734=[""].join("\n");
var outline_f17_20_17734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF MONITORING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type 1 devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type 2 devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type 3 devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type 4 devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3478043\">",
"      New classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Titration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reassessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULSE OXIMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7694|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/5/10326\" title=\"figure 1\">",
"      Home sleep tracing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/52/19275\" title=\"table 1\">",
"      Home recording in OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8413\" title=\"table 2\">",
"      SCOPER categorization system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=related_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_20_17735="Exocrine pancreatic cancer: Palliation of symptoms";
var content_f17_20_17735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exocrine pancreatic cancer: Palliation of symptoms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Carlos Fernandez-del Castillo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Ramon E Jimenez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17735/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17735/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/20/17735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 45,220 people develop cancer of the exocrine pancreas each year in the United States, and almost all are expected to die from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median survival is 8 to 12 months for patients with locally advanced, unresectable pancreatic cancer and only three to six months for those with metastatic disease at presentation. Surgical resection offers the only chance of cure. However, only 15 to 20 percent of patients have resectable disease at initial diagnosis; the majority have either locally advanced or metastatic cancer. The prognosis of pancreatic cancer is poor even in those with potentially resectable disease. Despite potentially curative resection, the five-year survival following pancreaticoduodenectomy is only about 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palliative treatment designed to control the symptoms of unresectable or recurrent pancreatic cancer can provide relief of obstructive jaundice, gastric outlet obstruction, pain and pancreatic exocrine insufficiency. This topic review will summarize an approach to these issues. A discussion on the management of patients with locally advanced pancreatic cancer (who may be eligible for chemotherapy and radiation-based therapy) and chemotherapy treatment for advanced disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .) The American Gastroenterological Association (AGA) guidelines for pancreatic ductal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/6\">",
"     6",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/\">",
"     file://www.gastro.org/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     JAUNDICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrelieved jaundice from an obstructed biliary tree causes pruritus, and it increases the risk for cholangitis. Palliation of jaundice in patients who are not undergoing an attempt at surgical resection is usually accomplished by the placement of an expandable metal stent. Surgery is reserved for those in whom stent placement is not possible due to technical reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgical options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical options for achieving biliary decompression include an anastomosis between the gallbladder and jejunum (cholecystojejunostomy) or common bile duct and jejunum (choledochojejunostomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. A cholecystojejunostomy should only be considered if the cystic duct enters the common bile duct at a site distant from the tumor. A choledochojejunostomy should only be performed if the common duct is &gt;1 cm in diameter. Drainage is successful in returning the serum bilirubin concentration in approximately 90 percent of patients; in the remainder, persistent hyperbilirubinemia may be seen due impaired hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One advantage of surgical bypass is the ability to perform prophylactic or therapeutic gastrojejunostomy to avoid gastroduodenal obstruction and celiac plexus block for pain control (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Pain'",
"    </a>",
"    below). However, the risk associated with surgery in these typically debilitated patients is not small. In one report, the postoperative mortality and perioperative morbidity rates were 3.1 and 22 percent, respectively, and the median survival was 6.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents can provide minimally invasive effective palliation of jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/11\">",
"     11",
"    </a>",
"    ]. Most jaundiced patients can be successfully managed using stents, and relatively few require surgical biliary-enteric bypass as a planned palliative procedure. Randomized trials and a meta-analysis have shown no difference in survival between endoscopic stent placement and surgical bypass for malignant obstructive jaundice; while stented patients have more frequent readmissions for stent occlusion, recurrent jaundice, and cholangitis, but lower morbidity and procedure-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/12-16\">",
"     12-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718237155\">",
"    <span class=\"h3\">",
"     Plastic versus metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of plastic and metal stents, both covered and uncovered, are available for endoscopic deployment. A systematic review and a meta-analysis concluded that compared with plastic stents, metal stents had a lower risk of recurrent obstruction but were not superior with regard to technical success, therapeutic success, mortality, or complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. As a result, the decision to use one versus another should be guided by expected length of survival, quality of life, costs, and physician expertise: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link&amp;anchor=H1135516949#H1135516949\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Types of stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated endoscopic retrograde cholangiopancreatographies, since the median duration of patency is about three months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link&amp;anchor=H17011418#H17011418\">",
"       \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Patency of plastic stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metal stents extend the duration of stent patency (approximately 8 to 12 versus 2 to 5 months). However, metal stents have significantly higher costs and may not be removable. Thus, the diagnosis of malignant disease must be firmly established before a metal stent is deployed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link&amp;anchor=H17011425#H17011425\">",
"       \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Plastic versus metal stents'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      A patient&rsquo;s treatment plan may not be known during the initial endoscopic retrograde cholangiopancreatography (eg, if biliary drainage is required before staging can be completed). Options in this setting include placing a plastic (and thus easily removed) stent or a self-expanding metal stent (which provides longer-term patency). A Monte Carlo decision analysis compared several strategies in patients with obstructive jaundice from pancreatic cancer with an undetermined surgical plan, and the results suggested that a short-length self-expanding metal stent is the preferred initial treatment for overall cost minimization [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In general, the placement of a metal stent could be considered in patients with potentially resectable pancreatic cancer, especially if surgery is likely to be delayed (eg, for neoadjuvant chemotherapy). However, this is a controversial area and some surgeons prefer a plastic stent in this setting. It may be helpful to speak with the surgeon prior to stent placement if a patient appears to have a potentially resectable tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718237106\">",
"    <span class=\"h3\">",
"     Covered versus uncovered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated differences in stent patency rates between covered and uncovered metal stents for the treatment of distal malignant biliary disease; despite showing significantly less tumor ingrowth, patency rates are not higher for covered stents. This can likely be explained by the many other etiologies of stent occlusion other than tumor ingrowth, including tumor overgrowth and stent obstruction by debris and biliary sludge. One potential benefit of the covered metal stents is that they are more easily removable than are uncovered metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], but one disadvantage is a higher incidence of cholecystitis from extrinsic occlusion of the cystic duct. As noted above, the use of a metal stent in a patient who is a candidate for resection should be reviewed with the surgeon prior to placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link&amp;anchor=H1135517058#H1135517058\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link&amp;anchor=H7922550#H7922550\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Covered versus uncovered metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718236285\">",
"    <span class=\"h3\">",
"     Percutaneous versus endoscopic stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether percutaneous approaches hold any advantage over endoscopic drainage approaches is unclear. At least one controlled trial of 75 patients with malignant bile duct obstruction demonstrated that patients treated with an endoscopic stent had a higher success rate for relief of jaundice (81 versus 61 percent) and a significantly lower 30-day mortality rate (15 versus 33 percent) than did those whose stents were placed percutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/14\">",
"     14",
"    </a>",
"    ]. However, other trials have shown exactly the opposite result, with higher therapeutic success rates and lower rates of early cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other complications may be more frequent with percutaneous approaches to drainage (eg, bile leaks and bleeding), potentially increasing morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/14,22\">",
"     14,22",
"    </a>",
"    ]. Furthermore, percutaneous stents are usually left to open drainage external to the body, at least initially, and this is often inconvenient to the patient and can create fluid and electrolyte disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DUODENAL OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of patients with pancreatic cancer will develop duodenal obstruction leading to gastric outlet obstruction, although it is typically not present at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/7\">",
"     7",
"    </a>",
"    ]. To avoid this complication, many surgeons create a prophylactic palliative gastrojejunostomy with a biliary bypass in those who are deemed to be unresectable at exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/7\">",
"     7",
"    </a>",
"    ]. The benefit of a prophylactic gastrojejunostomy in this setting was shown in a meta-analysis of three prospective trials comparing prophylactic gastroenterostomy plus biliodigestive anastomosis versus no bypass or a biliodigestive bypass alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/23\">",
"     23",
"    </a>",
"    ]. For patients undergoing prophylactic gastroenterostomy, the risk of a gastric outlet obstruction during follow-up was significantly lower (odds ratio 0.06, 95% CI 0.02 to 0.21), while rates of postoperative morbidity (including delayed gastric emptying) and mortality were not higher. The average duration of hospital stay was three days longer in the group that had prophylactic gastroenterostomy.",
"   </p>",
"   <p>",
"    Despite these data, the real benefit of this procedure in patients with unresectable pancreatic cancer has been questioned. An open surgical procedure to treat biliary or gastric obstruction is not needed in the vast majority of patients with unresectable pancreatic cancer who do not undergo initial laparotomy (98 percent in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/24\">",
"     24",
"    </a>",
"    ]). Furthermore, delayed gastric emptying is not infrequent after a prophylactic gastrojejunostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, our practice is to routinely perform a posterior retrocolic gastrojejunostomy whenever biliary bypass is performed, regardless of the presence or absence of symptoms of gastric outlet obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Expandable metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopically placed expandable metal stents are emerging as a more favorable option for patients with symptomatic gastric outlet obstruction. Early experience supports palliative benefit with lack of morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. One report, for example, focused on 29 patients who underwent 31 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/32\">",
"     32",
"    </a>",
"    ]. Obstruction was due to pancreatic cancer in 42 percent of the group. The patients' course was compared to those who underwent surgical gastrojejunostomy. The outcome for stent placement was considered to be good in 25 patients (81 percent). No immediate complications were attributed to stent placement. Reobstruction by tumor ingrowth occurred in two patients after an average of 183 days. The median survival was similar to those who underwent surgical gastrojejunostomy (94 versus 92 days, respectively). However, the duration of hospitalization was significantly shorter (4 versus 14 days) and the cost of stent placement was substantially less ($9,921 versus $28,173). Thus, duodenal stents are a reasonable option provided that an experienced endoscopist familiar with the technique is available. This topic is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DELAYED GASTRIC EMPTYING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 60 percent of patients with pancreatic cancer have slowed gastric emptying without evidence of gastroduodenal tumor invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/33\">",
"     33",
"    </a>",
"    ]. A possible explanation is tumor infiltration into the nerve plexuses. Approximately one-third of these patients experience nausea and vomiting, which may be erroneously attributed to gastric or duodenal obstruction. However, a gastrojejunostomy is ineffective in relieving symptoms in such patients. Unfortunately, vomiting is often difficult to control, although prokinetic agents may help [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain can be a significant feature of advanced pancreatic cancer. Often, palliation of pain can be successfully achieved by opioid analgesics alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasingly used approach is celiac plexus neurolysis (CPN), a chemical splanchnicectomy of the celiac plexus, which ablates the afferent nerve fibers that transmit pain from intraabdominal viscera via local injection of absolute alcohol. CPN can be performed percutaneously, surgically, or under endosonographic guidance. In the past, it has been most commonly performed intraoperatively or percutaneously with fluoroscopic or computed tomographic guidance. More recent experience has demonstrated that it can also be safely performed during endoscopic ultrasonography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CPN appears to be more effective than pharmacologic therapy both for immediate and long-term relief of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/34\">",
"     34",
"    </a>",
"    ]. The role of CPN in the treatment of cancer-related pain is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy may also significantly alleviate pain due to local invasion of pancreatic cancer. External beam radiation with or without concomitant chemotherapy is associated with resolution of cancer-related pain in 35 to 65 percent of patients and frequently with improvement in cachexia and obstructive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/35\">",
"     35",
"    </a>",
"    ]. However, it may take several weeks to achieve its maximal effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is common in patients with pancreatic cancer. Patients who are depressed experience a significant worsening of their quality of life and have more intense pain compared to those who are not depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/36\">",
"     36",
"    </a>",
"    ]. These features can be improved with adequate treatment of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MALABSORPTION AND WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss and cachexia in patients with pancreatic cancer are usually multifactorial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .) One contributory factor may be pancreatic exocrine insufficiency, which leads to fat malabsorption. Fat malabsorption usually occurs only in patients with cancer of the pancreatic head causing obstruction of the main pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Fat malabsorption does not become evident until lipase secretion is less than 10 percent of normal levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are suspected of having fat malabsorption should be treated with pancreatic enzyme replacement. Two small studies comparing this approach to no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/38\">",
"     38",
"    </a>",
"    ] or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17735/abstract/40\">",
"     40",
"    </a>",
"    ] suggested that supplements were associated with improved weight gain and decreased fat and protein malabsorption. If these preparations are used, adequate doses of lipase (30,000 IU) should be given, since this is the minimal amount needed to correct steatorrhea. As an example, one of the more commonly used enteric preparations contains approximately 8800 IU. Thus at least three to four capsules are required with each meal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .) Determining the adequate amount of lipase can be confusing since the amount of lipase in pancreatic supplements is typically expressed in USP units. One IU is equivalent to approximately 2 to 3 USP units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15023904\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative treatment designed to control the symptoms of unresectable or recurrent pancreatic cancer can provide relief of obstructive jaundice, gastric outlet obstruction, pain and pancreatic exocrine insufficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliation of jaundice in patients with pancreatic cancer who are not undergoing an attempt at surgical resection is usually accomplished by the placement of an expandable metal stent. Surgery is reserved for those in whom stent placement is not possible due to technical reasons. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Jaundice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopically placed expandable metal stents are also preferred over palliative gastrojejunostomy for patients with symptomatic gastric outlet obstruction. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Expandable metal stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain can be a significant feature of advanced pancreatic cancer. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Often, palliation of pain can be successfully achieved by opioid analgesics alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Celiac plexus neurolysis appears to be more effective than pharmacologic therapy both for immediate and long-term relief of pain in patients with pancreatic cancer, and it can be performed percutaneously or during endoscopic ultrasound. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link&amp;anchor=H9#H9\">",
"       \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\", section on 'Efficacy for pancreatic cancer pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy may also significantly alleviate pain due to local invasion of pancreatic cancer; however, it may take several weeks to see the maximal effect.",
"     </li>",
"     <li>",
"      Weight loss and cachexia in patients with pancreatic cancer are usually multifactorial. One contributory factor may be pancreatic exocrine insufficiency, which leads to fat malabsorption. Patients who are suspected of having fat malabsorption should be treated with pancreatic enzyme replacement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malabsorption and weight loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/2\">",
"      Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/3\">",
"      Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/4\">",
"      Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004; 139:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/5\">",
"      Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/6\">",
"      American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/7\">",
"      Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 1990; 212:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/8\">",
"      Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 1992; 79:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/9\">",
"      de Rooij PD, Rogatko A, Brennan MF. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br J Surg 1991; 78:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/10\">",
"      Sohn TA, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 1999; 188:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/11\">",
"      Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006; :CD004200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/12\">",
"      Andersen JR, S&oslash;rensen SM, Kruse A, et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/13\">",
"      Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/14\">",
"      Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/15\">",
"      Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/16\">",
"      Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/17\">",
"      Levy MJ, Baron TH, Gostout CJ, et al. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol 2004; 2:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/18\">",
"      Chen VK, Arguedas MR, Baron TH. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastroenterol Hepatol 2005; 3:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/19\">",
"      Kahaleh M, Brock A, Conaway MR, et al. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy 2007; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/20\">",
"      Shin HP, Kim MH, Jung SW, et al. Endoscopic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy 2006; 38:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/21\">",
"      Saluja SS, Gulati M, Garg PK, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/22\">",
"      Pi&ntilde;ol V, Castells A, Bordas JM, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology 2002; 225:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/23\">",
"      H&uuml;ser N, Michalski CW, Schuster T, et al. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. Br J Surg 2009; 96:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/24\">",
"      Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg 1999; 188:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/25\">",
"      Doberneck RC, Berndt GA. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 1987; 122:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/26\">",
"      Soetikno RM, Lichtenstein DR, Vandervoort J, et al. Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent. Gastrointest Endosc 1998; 47:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/27\">",
"      Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 2004; 60:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/28\">",
"      Mosler P, Mergener KD, Brandabur JJ, et al. Palliation of gastric outlet obstruction and proximal small bowel obstruction with self-expandable metal stents: a single center series. J Clin Gastroenterol 2005; 39:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/29\">",
"      Jung GS, Song HY, Kang SG, et al. Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. Radiology 2000; 216:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/30\">",
"      Venu RP, Pastika BJ, Kini M, et al. Self-expandable metal stents for malignant gastric outlet obstruction: a modified technique. Endoscopy 1998; 30:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/31\">",
"      Adler DG, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol 2002; 97:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/32\">",
"      Yim HB, Jacobson BC, Saltzman JR, et al. Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. Gastrointest Endosc 2001; 53:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/33\">",
"      Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci 1986; 31:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/34\">",
"      Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/35\">",
"      Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/36\">",
"      Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/37\">",
"      Passik SD, Breitbart WS. Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 1996; 78:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/38\">",
"      Perez MM, Newcomer AD, Moertel CG, et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983; 52:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/39\">",
"      DiMagno EP, Malagelada JR, Go VL. The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc 1979; 54:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17735/abstract/40\">",
"      Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998; 42:92.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2505 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17735=[""].join("\n");
var outline_f17_20_17735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15023904\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      JAUNDICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgical options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718237155\">",
"      - Plastic versus metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718237106\">",
"      - Covered versus uncovered stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718236285\">",
"      - Percutaneous versus endoscopic stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DUODENAL OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Expandable metal stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DELAYED GASTRIC EMPTYING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MALABSORPTION AND WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15023904\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_20_17736="Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)";
var content_f17_20_17736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17736/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17736/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/20/17736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1,4 linked glucose, interrupted by a 1,6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen is the primary source of energy for high-intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review acid maltase (alpha glucosidase) deficiency (GSD II, MIM #232300), which has infantile as well as juvenile and adult forms. An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysosomal acid maltase (acid alpha glucosidase) is needed to hydrolyze both alpha-1,4- and alpha-1,6-glucosidic linkages in the low pH environment of the lysosome. Deficiency of the enzyme leads to accumulation of glycogen in lysosomes and cytoplasm, resulting in tissue destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/1\">",
"     1",
"    </a>",
"    ]. The effect of the enzyme deficiency may extend to vesicle systems that are linked to lysosomes and may also affect receptors, such as glucose transporter 4, that cycle through these organelles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/2\">",
"     2",
"    </a>",
"    ]. Enzyme activity is absent or minimal in patients with infantile onset and variably reduced in those with late-onset [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of Pompe disease was estimated in a study in the Netherlands that screened newborn blood spots for the three common mutant alleles in that population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/4\">",
"     4",
"    </a>",
"    ]. This predicted an overall disease frequency of 1 in 40,000, with an incidence of 1 in 138,000 for classic infantile disease and 1 in 57,000 for late-onset disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pompe disease is an autosomal recessive disorder with considerable allelic heterogeneity. It is caused by mutations in the gene encoding lysosomal alpha-1,4-glucosidase (GAA) located at 17q25.2-q25.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. More than 200 mutations have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infantile form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic infantile form is characterized by cardiomyopathy and severe generalized muscular hypotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/8\">",
"     8",
"    </a>",
"    ]. The tongue may be enlarged. Hepatomegaly also may be present and is usually due to heart failure. There is no metabolic derangement. Infants with classic GSD II typically present during the first few months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/9\">",
"     9",
"    </a>",
"    ]. A \"non-classic\" phenotype with presentation during the first one to two years of life has also has been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link\">",
"     \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Without treatment, most patients with the classic infantile form have unremitting deterioration, with death during the first one to two years of age from cardiac insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, prolonged survival has been reported in infants with less severe cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of disease was illustrated in a review of 168 patients who presented by 12 months of age, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age at symptom onset was two months and at diagnosis was 4.7 months. Findings present at a median age of approximately four months included cardiomegaly (92 percent), respiratory distress (78 percent), muscle weakness (63 percent), feeding difficulties (57 percent) and failure to thrive (53 percent).",
"     </li>",
"     <li>",
"      The median age at first ventilator support was 5.9 months (range 0.1 to 31 months); ventilator-free survival rates at 12 and 18 months were 16.9 percent and 6.7 percent, respectively.",
"     </li>",
"     <li>",
"      The median age at death was 8.7 months (range 0.3 to 73 months); survival rates at 12 and 18 months were 26 and 12 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings highlight the need for early diagnosis and prompt initiation of enzyme replacement therapy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Enzyme replacement therapy (ERT) enhances survival in infants with lysosomal acid maltase deficiency. Surviving infants may develop complications of the disease, one of which appears to be fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/14\">",
"     14",
"    </a>",
"    ]. In a series of 15 fractures in 10 infants receiving ERT, the median age at the time of the first fracture was 22.7 months (range 13 months to 8 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/14\">",
"     14",
"    </a>",
"    ]. Most of the fractures occurred with no or only minimal trauma (eg, during physical therapy). Decreased bone density related to immobility, decreased weight bearing, feeding difficulties, and medications (eg, calciuric diuretics, glucocorticoids) may contribute to fracture risk. Other complications seen in patients treated with ERT include facial muscle weakness, speech disorders, and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/15\">",
"     15",
"    </a>",
"    ]. Cognitive outcome is good, with normal to only mildly delayed development seen in one small series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/16\">",
"     16",
"    </a>",
"    ]. The ability to accurately assess cognitive development in children &lt;5 years of age was affected by their degree of motor problems in this series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Juvenile and adult forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset Pompe disease may present at any age, even in patients with identical mutations, suggesting that secondary factors influence the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/13,17-19\">",
"     13,17-19",
"    </a>",
"    ]. In a multinational survey of 255 children and adults (aged 2.6 to 81 years) with late-onset Pompe disease, the age at first complaint ranged from 0 to 62 years and the age at diagnosis from 0 to 66 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/17\">",
"     17",
"    </a>",
"    ]. In a survey of 54 Dutch patients, the mean age of onset of symptoms was 28 years, but 18 percent of patients had symptoms before age 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the juvenile and adult forms, the primary clinical finding is skeletal myopathy, with a more protracted course leading to respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/20\">",
"     20",
"    </a>",
"    ]. Affected children usually present with delayed gross-motor development and progressive weakness in a limb-girdle distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/13\">",
"     13",
"    </a>",
"    ]. Early involvement of the diaphragm is a common feature, and sleep-disordered breathing may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/21\">",
"     21",
"    </a>",
"    ]. This usually leads to respiratory failure and death in the second or third decade of life. Older children with Pompe disease usually do not have cardiomegaly.",
"   </p>",
"   <p>",
"    Adult patients also present with progressive proximal weakness in a limb-girdle distribution, with associated diaphragmatic involvement leading to respiratory insufficiency early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/22\">",
"     22",
"    </a>",
"    ]. The heart and liver are not involved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Dilative arteriopathy, carotid artery dissection, and basilar artery dolichoectasia have been reported in a small number of patients with late-onset Pompe disease; however, the real incidence of these vascular complications is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of progression and sequence of respiratory and skeletal involvement varies substantially between patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/13,17,18,26\">",
"     13,17,18,26",
"    </a>",
"    ]. In the multinational survey described above, disease severity was related to disease duration rather than age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/17\">",
"     17",
"    </a>",
"    ], with the odds for wheelchair use and respiratory support increasing by 13 percent and 8 percent, respectively, for every additional year since diagnosis. Two-year follow-up of 52 Dutch patients with untreated late-onset Pompe disease indicated progressive decline, at the group level, in functional activities, respiratory function, handicap, and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Pompe disease should be suspected in an infant with profound hypotonia and cardiac insufficiency. The electrocardiogram reveals a short PR interval with giant QRS complexes in all leads, suggesting biventricular hypertrophy, although this is not unique to Pompe disease.",
"   </p>",
"   <p>",
"    In the juvenile and adult forms, the electromyogram is characteristic, with evidence of myopathic discharges sometimes associated with abundant myotonic and complex repetitive discharges most prominent in the paraspinal muscles. The vital capacity typically is reduced substantially in adults. The forearm ischemic lactate test is normal in patients with AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the metabolic myopathies\", section on 'Ischemic exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum creatine kinase is typically elevated in all types of Pompe disease, and leukocyte acid maltase activity is usually decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The discovery that acarbose is a selective inhibitor of neutral alpha-glucosidase allowed for selective measurement of acid alpha-glucosidase enzyme activity in white blood cells and dried blood spots. This assay is a reliable detection tool for the diagnosis of infantile Pompe disease. Acid maltase enzyme activity is also reduced in fibroblasts obtained by skin biopsy. This is more reliable than the leukocyte assay. Pseudodeficiency has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the availability of enzyme therapy, the value of newborn screening is being addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/31\">",
"     31",
"    </a>",
"    ]. A direct multiplex assay measuring lysosomal enzymes in dried blood spots by tandem mass spectrometry was developed to screen for Pompe disease and other lysosomal storages diseases in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/32\">",
"     32",
"    </a>",
"    ]. The feasibility and impact of newborn screening based upon enzyme analysis in dried blood spots were demonstrated in a nationwide pilot study in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. More than 206,000 newborns (approximately 45 percent) were screened; repeat samples and additional evaluation were required for fewer than 1 percent of infants. Six infants were detected through screening [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/34\">",
"     34",
"    </a>",
"    ]. The number of infants with confirmed Pompe disease was similar in the screened and unscreened populations, but the infants who were screened were diagnosed earlier (&lt;1 month versus three to six months of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early treatment of infants detected through screening was associated with normalization or improvement in cardiac size, muscle pathology, growth, and motor development [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/34\">",
"     34",
"    </a>",
"    ]. Survival was significantly improved compared with untreated historical controls, but not compared with treated patients who were diagnosed clinically.",
"   </p>",
"   <p>",
"    Assay of lysosomal alpha-1,4-glucosidase (GAA) activity in dried blood spots is also being evaluated as a noninvasive method of screening older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/35\">",
"     35",
"    </a>",
"    ]. Measurement of GAA activity in another tissue (skin fibroblast or muscle) or GAA gene sequencing is necessary for final confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy reveals vacuolar myopathy with glycogen storage within lysosomes, and free glycogen in the cytoplasm by electron microscopy. The vacuoles are periodic acid-Schiff (PAS) positive, digestible by diastase, and positive for acid phosphatase. Similar lysosomal inclusions are found in a variety of other tissues in infantile disease. Acid maltase activity in muscle is reduced to less than 10 percent of normal.",
"   </p>",
"   <p>",
"    While muscle biopsy provides information that is useful diagnostically, less invasive testing (eg, assay of acid maltase activity from leukocytes or from fibroblasts obtained by skin biopsy) may suffice to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is possible by DNA analysis if the mutation in the family is known. If the genetic defect is not known, acid maltase activity can be measured in cultured amniocytes or chorionic villus samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme replacement therapy (ERT) with recombinant human acid maltase derived from Chinese hamster ovary cells (alpha-glucosidase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    , Myozyme) was approved by the United States Food and Drug Administration (FDA) in 2006 for use in patients with Pompe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/37\">",
"     37",
"    </a>",
"    ]. Institution of enzyme replacement therapy has been reported as early as 18 hours of age with positive short-term results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prelicensure trial of 18 patients with infantile-onset disease who were treated with 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    every two weeks, all 18 of the patients survived to age 18 months (compared to only 1 of 61 historic controls) and 13 had improved motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/39\">",
"     39",
"    </a>",
"    ]. Seven of the treated patients required ventilatory support, and there were two deaths, one after 14 months of treatment, and one after 25 months. In an extension of the trial, the 16 surviving patients continued therapy for up to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/40\">",
"     40",
"    </a>",
"    ]. Over the entire study period, alglucosidase alfa therapy was associated with a 95 percent reduction in the risk of death, a 91 percent reduction in the risk of invasive ventilation, and continued improvement in cardiomyopathy and motor skills.",
"   </p>",
"   <p>",
"    In a second trial, 21 patients (3 months to 3.5 years at initiation) were treated with 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    every other week for 104 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/41\">",
"     41",
"    </a>",
"    ]. Treatment with alglucosidase alfa was associated with a 79 percent reduction in the risk of death, a 58 percent reduction in the risk of invasive ventilation, improvement or stabilization of left ventricular mass, and improved motor milestones.",
"   </p>",
"   <p>",
"    In other small, open-label studies, intravenous enzyme replacement with recombinant human alpha-glucosidase from transgenic rabbit milk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Chinese hamster ovary cells led to improvement in some clinical parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/42-46\">",
"     42-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment outcome in infantile Pompe disease appears to be affected by cross-reactive immunologic material (CRIM) status [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/47\">",
"     47",
"    </a>",
"    ]. In retrospective analysis of 32 patients who were treated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    , CRIM-negative status (lacking any residual GAA expression) was associated with increased risk of death or invasive ventilation after 52 weeks of therapy (54.5 versus 4.8 percent in CRIM-positive patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/47\">",
"     47",
"    </a>",
"    ]. Antibodies to alglucosidase alfa develop earlier and antibody titers are higher and more sustained in CRIM-negative patients, suggesting that antibody interference may attenuate the treatment response. This hypothesis is supported by studies demonstrating enhanced response to enzyme replacement therapy following induction of immune tolerance in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/48-50\">",
"     48-50",
"    </a>",
"    ] and a CRIM-negative infant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous ERT with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    (Lumizyme) has also shown efficacy for late-onset Pompe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/52-57\">",
"     52-57",
"    </a>",
"    ] and was approved by the US Food and Drug Administration (FDA) in 2010 for use in patients eight years of age and older with late-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/58\">",
"     58",
"    </a>",
"    ]. In a multicenter trial, 90 patients aged 10 to 70 years were randomized 2:1 to biweekly intravenous alglucosidase alfa (20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo for 78 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/57\">",
"     57",
"    </a>",
"    ]. Treatment with alglucosidase alfa led to improved walking distance and pulmonary function, whereas these measures declined in the placebo group. The estimated differential treatment effect was 28.1 m for the six minute walk test and 3.4 percent for the change in forced vital capacity (FVC). A small, open-label study of four adult patients aged 39 to 68 years treated with ERT for six months demonstrated improvement in analytes, such as creatine kinase and transaminases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/56\">",
"     56",
"    </a>",
"    ]; in three patients, symptoms of respiratory insufficiency improved. Whether long-term benefits to adults occur with ERT remains to be established.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/44/44741?source=see_link\">",
"     alglucosidase alfa",
"    </a>",
"    infusion include severe hypersensitivity reaction, acute cardiorespiratory failure, and infusion reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The majority of patients in the two clinical trials developed antibodies to alglucosidase alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As discussed above, antibodies to alglucosidase alfa develop earlier and antibody titers are higher and more sustained in CRIM-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene therapy strategies are under investigation and results from a mouse model are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high-protein and low-carbohydrate diet combined with exercise therapy may be helpful in adult-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. A combination of high-protein and low-carbohydrate diet may be even more beneficial to older children, adolescents, and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both childhood and adult cases that progress to respiratory failure, mechanical ventilation is usually necessary. Noninvasive ventilation during sleep may improve nighttime hypoxemia and daytime hypercapnia in some juvenile- and adult-onset patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/21,65\">",
"     21,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A list of Web sites for organizations and support groups for patients with acid maltase deficiency and their families is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef69680 \" href=\"UTD.htm?9/62/10219\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17736/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lysosomal acid maltase deficiency (Pompe disease) is an autosomal recessive disorder with considerable allelic heterogeneity. It is caused by mutations in the gene for lysosomal alpha-1,4-glucosidase. Deficiency of lysosomal acid maltase leads to accumulation of glycogen in lysosomes and cytoplasm (",
"      <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"       figure 1",
"      </a>",
"      ), which results in tissue destruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infantile form of Pompe disease is characterized by cardiomyopathy and severe generalized hypotonia. Tongue enlargement and hepatomegaly are variable findings. Without treatment, most patients die within the first year or two of life. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Infantile form'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The juvenile and adult forms are characterized by skeletal myopathy (usually in a limb-girdle distribution) and a protracted course leading to respiratory failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Juvenile and adult forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infantile-onset Pompe disease should be suspected in infants with profound hypotonia and cardiac insufficiency. Juvenile or adult-onset Pompe disease should be considered in patients with progressive weakness in a limb-girdle distribution. Demonstration of reduced acid maltase activity in leukocytes, fibroblasts, or muscle confirms the diagnosis.",
"      <br/>",
"      <br/>",
"      Supportive findings may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Electrocardiogram demonstrating short PR interval and giant QRS complexes in all leads, suggesting biventricular hypertrophy, although this is a nonspecific finding (infantile form).",
"     </li>",
"     <li>",
"      Electromyogram demonstrating myopathic discharges sometimes associated with abundant myotonic and complex repetitive discharges most prominent in the paraspinal muscles (juvenile and adult forms).",
"     </li>",
"     <li>",
"      Elevated serum creatine kinase (both forms).",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pompe disease is treated with enzyme replacement therapy, diet (high-protein, low carbohydrate), exercise, and supportive care (eg, mechanical ventilation for respiratory failure). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/1\">",
"      Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/2\">",
"      Orth M, Mundegar RR. Effect of acid maltase deficiency on the endosomal/lysosomal system and glucose transporter 4. Neuromuscul Disord 2003; 13:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/3\">",
"      Nascimbeni AC, Fanin M, Tasca E, Angelini C. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology 2008; 70:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/4\">",
"      Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999; 7:713.",
"     </a>",
"    </li>",
"    <li>",
"     Engel A, Hirschhorn R. Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1994. p.1533.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/6\">",
"      Martiniuk F, Mehler M, Tzall S, et al. Sequence of the cDNA and 5'-flanking region for human acid alpha-glucosidase, detection of an intron in the 5' untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences. DNA Cell Biol 1990; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/7\">",
"      Kroos M, Pomponio RJ, van Vliet L, et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 2008; 29:E13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/8\">",
"      Howell RR, Byrne B, Darras BT, et al. Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome. Genet Med 2006; 8:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/9\">",
"      Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology 2008; 71:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/10\">",
"      Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006; 148:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/11\">",
"      van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003; 112:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/12\">",
"      Slonim AE, Bulone L, Ritz S, et al. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000; 137:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/13\">",
"      Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005; 252:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/14\">",
"      Case LE, Hanna R, Frush DP, et al. Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol 2007; 37:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/15\">",
"      van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012; 35:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/16\">",
"      Ebbink BJ, Aarsen FK, van Gelder CM, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 2012; 78:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/17\">",
"      Hagemans ML, Winkel LP, Hop WC, et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005; 64:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/18\">",
"      Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005; 128:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/19\">",
"      Kroos MA, Pomponio RJ, Hagemans ML, et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T-&gt;G haplotype. Neurology 2007; 68:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/20\">",
"      Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain 1970; 93:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/21\">",
"      Nabatame S, Taniike M, Sakai N, et al. Sleep disordered breathing in childhood-onset acid maltase deficiency. Brain Dev 2009; 31:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/22\">",
"      Amato AA, Leep Hunderfund AN, Selcen D, Keegan BM. A 49-year-old woman with progressive shortness of breath. Neurology 2011; 76:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/23\">",
"      Tein I. Metabolic myopathies. Semin Pediatr Neurol 1996; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, Tonin P, Servidei S. Metabolic myopathies. In: Handbook of clinical neurology, Rowland L, DiMauro S (Eds), Elsevier, Amsterdam, The Netherlands 1992. p.479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/25\">",
"      Lafor&ecirc;t P, Petiot P, Nicolino M, et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 2008; 70:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/26\">",
"      Hagemans ML, Hop WJ, Van Doorn PA, et al. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 2006; 66:581.",
"     </a>",
"    </li>",
"    <li>",
"     Griggs R, Mendell J, Miller R. Metabolic myopathies. In: Evaluation and treatment of myopathies, Griggs R, Mendell J, Miller R (Eds), FA Davis Company, Philadelphia 1995. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/28\">",
"      Ausems MG, Lochman P, van Diggelen OP, et al. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 1999; 52:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/29\">",
"      Zhang H, Kallwass H, Young SP, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med 2006; 8:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/30\">",
"      Nishimoto J, Inui K, Okada S, et al. A family with pseudodeficiency of acid alpha-glucosidase. Clin Genet 1988; 33:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/31\">",
"      Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 2007; 120:e1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/32\">",
"      Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006; 29:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/33\">",
"      Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008; 122:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/34\">",
"      Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009; 124:e1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/35\">",
"      Goldstein JL, Young SP, Changela M, et al. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve 2009; 40:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/36\">",
"      Pompe Disease Diagnostic Working Group, Winchester B, Bali D, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 2008; 93:275.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Center for Drug Evaluation and Research. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=MYOZYME (Accessed on May 02, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/38\">",
"      Hamdan MA, Almalik MH, Mirghani HM. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results. J Inherit Metab Dis 2008; 31 Suppl 2:S431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/39\">",
"      Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/40\">",
"      Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/41\">",
"      Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/42\">",
"      Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005; 15:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/43\">",
"      Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/44\">",
"      Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/45\">",
"      Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113:e448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/46\">",
"      van Capelle CI, Winkel LP, Hagemans ML, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 2008; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/47\">",
"      Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010; 99:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/48\">",
"      Raben N, Nagaraju K, Lee A, et al. Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice. Transgenic Res 2003; 12:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/49\">",
"      Sun B, Bird A, Young SP, et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007; 81:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/50\">",
"      Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 2010; 18:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/51\">",
"      Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 2009; 360:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/52\">",
"      Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004; 55:495.",
"     </a>",
"    </li>",
"    <li>",
"     Myozyme&reg; (alglucosidase alfa) product label. Genzyme Corporation, Cambridge, MA, April 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/54\">",
"      Case LE, Koeberl DD, Young SP, et al. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 2008; 95:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/55\">",
"      Ravaglia S, Danesino C, Pichiecchio A, et al. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II. Adv Ther 2008; 25:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/56\">",
"      Merk T, Wibmer T, Schumann C, Kr&uuml;ger S. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults. Eur J Neurol 2009; 16:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/57\">",
"      van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362:1396.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Center for Drug Evaluation and Research. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=LUMIZYME (Accessed on June 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/59\">",
"      Poenaru L. Approach to gene therapy of glycogenosis type II (Pompe disease). Mol Genet Metab 2000; 70:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/60\">",
"      van Til NP, Stok M, Aerts Kaya FS, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 2010; 115:5329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/61\">",
"      Margolis ML, Hill AR. Acid maltase deficiency in an adult. Evidence for improvement in respiratory function with high-protein dietary therapy. Am Rev Respir Dis 1986; 134:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/62\">",
"      Slonim AE, Coleman RA, McElligot MA, et al. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology 1983; 33:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/63\">",
"      Slonim AE, Bulone L, Goldberg T, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007; 35:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/64\">",
"      Isaacs H, Savage N, Badenhorst M, Whistler T. Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry 1986; 49:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/65\">",
"      Mellies U, Stehling F, Dohna-Schwake C, et al. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 2005; 64:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17736/abstract/66\">",
"      Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004; 144:S35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2905 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17736=[""].join("\n");
var outline_f17_20_17736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infantile form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Juvenile and adult forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2905|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/62/10219\" title=\"table 2\">",
"      Pompe resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_20_17737="Chronic PE PA";
var content_f17_20_17737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54915%7EPULM%2F66676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54915%7EPULM%2F66676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic pulmonary embolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows mosaic oligemia with localization of pulmonary blood flow to the lower lobes. This may be regarded as a Westermark's sign with oligemia affecting the subtended pulmonary parenchyma of the upper lobes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic pulmonary embolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary angiogram shows mosaic oligemia with localization of pulmonary blood flow to the lower lobes. This may be regarded as a Westermark's sign with oligemia affecting the subtended pulmonary parenchyma of the upper lobes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17737=[""].join("\n");
var outline_f17_20_17737=null;
var title_f17_20_17738="Vascular calcification in chronic kidney disease";
var content_f17_20_17738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vascular calcification in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Behdad Afzali, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17738/contributors\">",
"     David JA Goldsmith, MA, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/20/17738/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/20/17738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of death in dialysis patients is cardiovascular disease (CVD). Increasingly, it is appreciated and accepted that this may be due in part to the presence of excess vascular calcification (VC), particularly in the form of extensive coronary artery calcification (CAC), which can be observed even in very young dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A key question is what drives the development and maintenance, or progression, of such abnormal calcification. Many diverse but also potentially interlinked factors have been incriminated. Despite the ongoing concern about the role of calcium-loading (eg, from calcium-containing oral phosphate binders [OPB]), such calcification was commonly noted in patients with renal disease during periods when calcium-containing OPBs were not yet available, or in patients exposed to little elemental calcium. This and the complex epidemiology suggest that probably many additional clinical factors are also associated with VC and CAC in the population with chronic kidney disease (CKD). Some of these features include Vitamin D therapy, increasing age, and dialysis vintage for those patients on dialysis programs.",
"   </p>",
"   <p>",
"    Calcium can be deposited into either the medial or intimal layers of the vasculature. The relationship between adverse cardiovascular outcomes and the particular location of calcium deposition is a source of both interest and some concern in the nephrology community.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most investigators now contend that calcium deposition in the medial layer, a common finding in dialysis patients, is associated with stiffening of the vasculature, resulting in significantly adverse cardiovascular outcomes.",
"     </li>",
"     <li>",
"      Intimal calcium deposition is principally associated with atherosclerotic plaques; in patients with normal renal function, such \"complex\" plaques are more often associated with myocardial infarction and thrombotic events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, it is likely that, among patients with renal disease, both intimal and medial calcification are co-localized in the coronary, aortic, and iliofemoral circulations. Whether these different lesions progress or behave in parallel is unclear.",
"   </p>",
"   <p>",
"    The implications of VC for patients with chronic kidney and options for prevention and treatment of these lesions are reviewed herein. The definition, diagnosis, pathogenesis, and molecular biology of VC in dialysis patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION AND QUANTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not clinically useful, the \"gold standard\" technique for the detection, assessment, and quantification of VC is the histological examination of post-mortem arterial specimens.",
"   </p>",
"   <p>",
"    A number of noninvasive methods have therefore been developed for the detection and quantification of VC. The simplest technique is plain radiography, with the salient features being pipe-stem calcification of the tunica media and internal elastic lamina. Although some degree of differentiation between intimal and medial calcification may be inferred from the use of plain films, this technique is both insensitive and difficult to quantify.",
"   </p>",
"   <p>",
"    CT scanning permits both the detection and quantification of the extent and severity of VC (although it does not differentiate between intimal and medial calcium deposition). Coronary artery calcification using special scanners and software has been the most widely studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other techniques have also been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular ultrasound can frequently show calcified plaques and calcified media, although intravascular ultrasound and optical coherence tomography offer further refinements in sensitivity.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ultrasonic/echocardiographic",
"      </span>",
"      signal backscatter analysis, energy subtraction radiography, and nuclear medicine bone tracer techniques can show the presence of calcium, at microscopic level, but these techniques do not differentiate between its presence in vessels or interstitium [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/6-8\">",
"       6-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2009 KDIGO guidelines have endorsed the use of plain lateral abdominal X-ray films or echocardiography to detect the presence or absence of vascular or valvular calcification, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/9\">",
"     9",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    We feel that is currently premature to screen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    follow vascular calcification in dialysis patients since no specific therapy is available beyond careful attention to calcium and phosphate balance. However, the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for cardiovascular disease suggest that if arterial calcification is identified by plain radiography in the abdominal aorta, carotid arteries, ileofemoral axis or femoropopliteal axis, then involvement of another site should be investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/10\">",
"     10",
"    </a>",
"    ]. If vascular calcification is found in two or more sites, then the workgroup also recommended that the use of a non-calcium containing phosphate binder could be considered. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sevelamer'",
"    </a>",
"    below.) There is however no clinical evidence at all that such an intervention applied at that stage would produce clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOW NEW IS THE EPIDEMIC OF VASCULAR CALCIFICATION?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of rare calcification syndromes, such as calcific uremic arteriolopathy, were first reported 100 or more years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/11\">",
"     11",
"    </a>",
"    ]. Large case series were also reported in the 1960s and 1970s, which was the beginning of the dialysis era [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/4,12,13\">",
"     4,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, vascular calcification in renal failure has also been previously observed. Cases dating from 1855 to 1945 (reviewed by Mulligan in 1949 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/14\">",
"     14",
"    </a>",
"    ]) were typically a consequence of severe hypercalcemia. The cases were typically osteolytic metastases, due principally to primary hyperparathyroidism, parathyroid carcinoma, and vitamin D toxicity.",
"   </p>",
"   <p>",
"    A difficult question is whether the present \"epidemic\" of VC is a new phenomenon or whether it is merely an old problem that emerged because of much greater awareness and better screening and imaging techniques. Most believe that there has been a genuine increase in the prevalence of vascular calcification over decades. Several lines of evidence have attempted to differentiate these two possibilities. These include results from post-mortem, radiographic, and EBCT studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autopsy studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular calcification is a common finding in autopsy studies of dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. The following is a sample of some studies that reported VC in renal patients during periods when calcium-based OPBs were not widely used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the predialysis era, one 1959 study reported the presence of VC in 18 of 29 patients (62 percent) with secondary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An autopsy study from the period 1966 to 1975 found that 44 of 56 dialysis patients (79 percent) and 8 of 18 predialysis chronic kidney disease patients (44 percent) had visceral (including myocardial) calcification [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/17\">",
"       17",
"      </a>",
"      ]. The correlation between severity and anatomical extent of calcification with bone biopsy findings, and parathyroid gland weight and histology was poor.",
"     </li>",
"     <li>",
"      In a study of 120 children who had died at a mean age of about 10 years with uremia between the years 1960 and 1983, 29 had cardiac calcifications, while 12 had coronary artery calcifications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last few decades, a large number of studies have found radiographic evidence of vascular calcification in a significant percentage of patients with renal dysfunction. The following are some sample studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 1976 report, 364 skeletal radiographic surveys in 152 patients with chronic renal failure revealed that 30 and 50 percent of 15- to 30-year-olds and 40- to 50-year-olds, respectively, had VC, which most commonly consisted of medial vascular calcification at the ankle [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/21\">",
"       21",
"      </a>",
"      ]. Progression was most marked in the non-dialyzed group, and least in those undergoing maintenance dialysis. The same group subsequently reported that all chronic peritoneal dialysis patients radiographed between 1980 and 1985 had some calcification (very mild in 58 percent and moderate to severe in 42 percent), with progression and regression occurring in 57 and 13 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that covered the period 1970 to 1994, an original annual skeletal survey of 38 long-term chronic hemodialysis patients was re-analyzed as a \"vascular\" survey [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/25\">",
"       25",
"      </a>",
"      ]. Aorto-iliac calcification was seen in 39 percent at the onset of dialysis, with the risk increasing with increasing age. After a mean period of 16 years on dialysis, 92 percent of patients had VC.",
"      <span class=\"nowrap\">",
"       Central/elastic",
"      </span>",
"      arteries appeared to calcify independently of smaller peripheral muscular ones. More severe VC was associated with increased patient age, dialysis vintage, pulse pressure, plasma phosphate levels, measured plasma vitamin D levels and severe hyperparathyroidism (as measured by intact PTH levels). Parathyroidectomy reduced, or abolished, further calcium accumulation in the vascular tree.",
"     </li>",
"     <li>",
"      A comprehensive systematic review of 30 studies over a period of 20 years demonstrated that age, length of time on dialysis therapy, and possibly dyslipidemia were the main associations with VC in patients with chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, the presence of calcification was a phenomenon consistently observed over the last several decades.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CT studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the use of electron beam or multislice CT in patients with renal disease, which have largely been performed during the period of widespread use of calcium-containing phosphate binders. The data are limited to a relatively small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/1-3,28-36\">",
"     1-3,28-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, CT has demonstrated a prevalence of CAC of 80 to 100 percent in adult patients on maintenance dialysis. Although the incidence is lower in children, CAC in children on dialysis progresses faster than in healthy adult patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many studies of chronic dialysis patients have shown near universal progression of CAC both on a cross-sectional basis and with limited follow-up. Some of the studies that best reveal the prevalence and progression of CAC using EBCT among dialysis patients are described in detail elsewhere within this topic review [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Calcium intake'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Prevention and treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is also a relatively limited amount of data concerning the prevalence of CAC using CT in patients with chronic kidney disease who are not yet on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/35,37-40\">",
"     35,37-40",
"    </a>",
"    ]. One study evaluated the association between CKD and CAC among 2660 participants in the Dallas Heart Study aged 30 to 65 years, of whom 211 had CKD as defined by National Kidney Foundation Stages 1 through 5 (with dialysis dependent patients excluded) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared to those without CKD, participants with stage 3 to 5 disease (GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) were at increased risk of having increased CAC, particularly very high calcification scores. This was largely due to the inclusion of patients with diabetes as there was no significant association between increased CAC scores and the nondiabetic population with stage 3 to 5 disease. In addition, no increase in CAC was noted in those with stage 1 and 2 disease (which is defined as GFR &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 plus microalbuminuria). Similar findings were reported from a smaller study of Hispanic individuals who underwent ultrafast spiral computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have found a significant increase in CAC among patients with CKD without diabetes and in whom the calcium, phosphate, and PTH levels did not appear to be different between CKD patients with calcifications and those without [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. In one study of 85 patients with CKD (mean GFR of 33",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and 55 individuals, CAC was noted in 40 percent of patients versus 13 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of calcium-containing OPBs, VC was clearly a frequent feature of patients with chronic kidney disease. Thus, the present epidemic of VC is not new [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, vascular calcium accumulation was, and still remains, very common, particularly after patients are established on dialysis.",
"   </p>",
"   <p>",
"    Analysis of many of these studies suggest that factors other than calcium intake and abnormalities of mineral metabolism may enhance the risk of vascular calcification. These include increasing age, increasing length of time on dialysis therapy (dialysis vintage), dyslipidemia, presence of diabetes, and increased pulse pressure. There is by consensus a central role for raised plasma phosphate levels. Most experts believe that a raised plasma phosphate with intermittent, episodic, or permanent, hypercalcemia, is a potent driver for the initiation and progression of vascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of calcium loading (persistently positive calcium balance, especially where the skeleton cannot buffer the excess of calcium) is clear; there are patients in whom this is the key driver for progressive vascular damage. In a situation where plasma phosphate (most likely the key biochemical driver for progressive calcification) is poorly controlled using large amounts of calcium-containing oral phosphate binders, there is a risk of recurrent hypercalcemia, calcium accumulation in soft tissues including blood vessels, and this may lead to increased morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MINERAL METABOLISM AND VASCULAR CALCIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although VC was clearly present in patients with renal disease prior to the widespread use of calcium-containing OPBs, a current hypothesis is that, by widely using such agents (as well as vitamin D) to help prevent uremic osteodystrophy, we have unwittingly accelerated widespread uremic vasculopathy. This has resulted in vascular stiffness in dialysis patients, thereby markedly contributing to premature cardiovascular mortality.",
"   </p>",
"   <p>",
"    The following is an overview of some of the clinical studies related to this issue. The biology of alterations in mineral metabolism and its effect upon the development and progression of vascular calcification is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcium intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, a variety of studies have reported that increased intake of calcium may directly enhance coronary arterial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/2,29,44\">",
"     2,29,44",
"    </a>",
"    ]. The potential impact upon CAC of using calcium as a phosphate binder was perhaps best assessed in 39 young dialysis patients (mean age 19 years) who underwent electron beam CT to detect coronary artery calcification and were compared to 60 age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/2\">",
"     2",
"    </a>",
"    ]. Coronary artery calcification was much more common in the patients undergoing maintenance hemodialysis (88 versus 5 percent in controls). Among the dialysis patients, the clinical features that distinguished the group with coronary artery calcification from those without such calcification included increased age (26 versus 15 years), duration of dialysis (14 versus 4 years), serum calcium-phosphorus product (65 versus 56",
"    <span class=\"nowrap\">",
"     mg2/dL2),",
"    </span>",
"    and daily dose of oral calcium (6456 versus 3325",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    However impressive the changes were, it has been pointed out that the dose of calcium was not corrected for body size, a potentially important variable in growth-retarded teenagers. Moreover, the serum concentrations of calcium alone and phosphorus alone were not significantly different between the two groups. Based upon this study, it is therefore unclear whether increased duration of dialysis, independent of calcium intake, enhanced the risk of arterial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence implicating increased calcium intake as causal in promoting vascular calcification was provided by a prospective study where 200 hemodialysis patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    or calcium-based phosphate binders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/3\">",
"     3",
"    </a>",
"    ]. At one year, although serum phosphorus control was similar with both agents, sevelamer was associated with a much lower percentage increase of the median absolute calcium scores in both the aorta and coronary arteries (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Sevelamer'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General alterations in mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in mineral metabolism, particularly plasma calcium and phosphate levels, appear to directly correlate with survival studies in dialysis patients as well as increased vascular calcification. Cross-sectional and (to a limited extent) prospective, epidemiological studies reveal a linear relationship between dialysis patients mortality and both plasma calcium concentration and the calcium-phosphate product. In addition, there is a U-shaped relationship between achieved dialysis plasma phosphate levels and mortality (both all-cause and cardiovascular). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vitamin D therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For decades, vitamin D therapy, especially in excess, has been recognized as a potential vascular toxin. Vitamin D, which has diverse, concentration-dependent effects, promotes plaque calcification and atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. From its inception as an \"extract\" of ergosterol, the ability of vitamin D to calcify (predominantly) the medial layer of arteries has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two clinical studies have demonstrated a correlation between vitamin D use and VC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One post-mortem investigation showed an association between vitamin D usage and VC in pediatric patients (with no association being found for calcium and phosphate) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a plain X-ray study of VC in hemodialysis patients, levels of vitamin D metabolites correlated with the extent and progression of VC [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the relationship between vascular calcification and vitamin D appears to be different in those without renal disease. In one study, for example, there was a favorable effect on large artery hemodynamics from the administration of vitamins D and K [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, clinically employed doses of vitamin D frequently result in hypercalcemia and an elevated calcium-phosphate product, which can accelerate extra-osseous calcification. The propensity to",
"    <span class=\"nowrap\">",
"     ectopic/soft",
"    </span>",
"    tissue calcification is also associated with adynamic bone disease due to excessive vitamin D dosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this, there is increasing evidence that the administration of native vitamin D (eg, cholecalciferol) to patients with low serum levels of vitamin D (which are very common in CKD) may be beneficial for survival. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Calciphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once rare calcification syndromes, such as calcific uremic arteriolopathy (calciphylaxis), are now being increasingly reported, frequently as necrotizing panniculitis or ascending acral gangrene. This has been associated in part with the increased use of calcium-containing oral phosphate binders and vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS OF VC IN CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, calcium can be deposited into either the medial or intimal layers of the vasculature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most investigators now contend that calcium deposition in the medial layer, a common finding in dialysis patients, is associated with stiffening of the vasculature, resulting in adverse cardiovascular outcomes.",
"     </li>",
"     <li>",
"      Intimal calcium deposition, also a common lesion in patients with chronic kidney disease, is principally associated with atherosclerotic plaques. In patients with normal renal function, intimal calcium deposition may be associated with myocardial infarction and thrombotic events. It is not clear if this is also true in advanced chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact on cardiovascular prognosis according to whether calcium was deposited in the intimal or medial layers of the vasculature was not directly examined by the previously cited studies that used EBCT and other modalities to detect vascular calcification in dialysis patients. One study that directly addressed this issue evaluated 202 stable hemodialysis patients with plain radiographs of the pelvis and the thigh for medial or intimal artery calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/4\">",
"     4",
"    </a>",
"    ]. All patients also underwent B-mode ultrasonography of the common carotid artery to determine the presence of atherosclerotic calcified plaques. Reported results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intimal calcification was primarily noted in relatively older patients with a clinical history of atherosclerosis and conventional risk factors for atherosclerotic disease.",
"     </li>",
"     <li>",
"      Medial calcification was observed in younger patients without conventional atherosclerotic risk factors, and was closely associated with the duration of hemodialysis and calcium-phosphate disorders. The latter included the oral dose of calcium as prescribed as a phosphate binder.",
"     </li>",
"     <li>",
"      Compared to those with intimal calcification, patients with medial disease had a longer survival. However, survival was less than that observed in those without calcifications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are only limited data in dialysis patients concerning the correlation of CAC assessed using EBCT with angiographically documented coronary disease or with subsequent outcomes, which are illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A correlation between CAC in dialysis patients and severity of atherosclerosis was shown in a study of 46 dialysis patients who underwent both an EBCT and a diagnostic coronary angiogram within a 12 month period [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/51\">",
"       51",
"      </a>",
"      ]. The total coronary artery calcification score directly correlated with the severity and number of diseased vessels.",
"     </li>",
"     <li>",
"      In a prospective study, 104 hemodialysis patients (mean age 56 years) underwent EBCT and were subsequently followed for a mean of 44 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/36\">",
"       36",
"      </a>",
"      ]. Mortality was higher among patients with CAC score above the median (98 versus 34 per 1000 patient years in those with CAC score below the median). However, in analyses adjusted for other known cardiovascular risk factors, the increase in risk of death associated with having a CAC score above the median was not statistically significant (relative risk 2.7, 95% CI 0.87 to 8.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In renal patients, we feel that VC that is localized to the media of blood vessels is principally linked to increased stiffness of large conduit arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. The reduced vascular compliance may lead to increased pulse pressure, reduced coronary perfusion, and abnormal autonomic, and endothelial vasomotor, functions. In addition, VC is associated with increased difficulty forming vascular anastomoses (vascular grafts or AV fistulae) or performing successful coronary artery interventions (angioplasty, stenting, and coronary artery bypass grafting [CABG]) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such overall vascular stiffness due to VC may have a profound negative effect upon survival for dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/5,53,54\">",
"     5,53,54",
"    </a>",
"    ]. In a well-designed study, quantitative CT scanning was used to assess the relationships among progressive calcification of the superficial femoral artery, concomitant femoral arterial stiffness, and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/5\">",
"     5",
"    </a>",
"    ]. At two years, progressive calcification was seen in 58 of 101 patients (57 percent), with increases in vascular calcification correlating with increases in arterial stiffness. Vascular calcification was present in practically all patients who died (20 of 21, 95 percent). By comparison, most patients with an initial calcification score of zero did not develop calcification over this period (31 of 46, 67 percent).",
"   </p>",
"   <p>",
"    In patients with normal renal function, calcium in an atherosclerotic plaque can also be a marker for a complex arterial lesion. Despite the relative lack of published clinical data in patients with renal dysfunction, increasing evidence suggests that atherosclerotic plaques in uremic subjects calcify at a much earlier developmental stage (at a point where luminal encroachment is minimal) than in patients without renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In one study, for example, coronary arteries taken post-mortem from patients with end-stage renal failure were characterized by increased intima and media thicknesses as well as marked calcification, but not by increased plaque size [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to those with normal renal function, there is also a higher load of calcium in vessel walls (intima and media) in uremic subjects. The calcification in this setting may exert a stabilizing effect on arterial plaque lesions by \"holding the artery open,\" thereby acting in many ways like a coronary stent. From a physical perspective, motion and stress are reduced in a segment of arterial calcification and ex vivo analysis of calcified plaques suggest increased resistance to rupture. However, an adjacent non-calcified segment (in practice at the beginning and the end of the cylinder of calcification) may paradoxically experience more wall stress.",
"   </p>",
"   <p>",
"    Some investigators have therefore challenged the classical construct, which appears valid in subjects with normal renal function, that atherosclerotic plaques containing calcium may engender plaque instability and promote potential rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/60\">",
"     60",
"    </a>",
"    ]. Instead, in uremia, arterial disease progression may be less as a result of acute plaque rupture and more due to chronic ischemia and fibrosis. This is mediated by progressive luminal obliteration (contributing to myocardial ischemia, fibrosis, myocardial electrical non-homogeneity, arrhythmia and sudden death) and increased vessel stiffness (which in the aorta leads to increased left ventricular (LV) mass).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinct, but potentially co-localizing, forms of VC, intimal and medial calcification, have been identified. These calcification patterns appear to have different clinical implications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of calcium in the intimal layer may be a marker for plaque vulnerable to rupture and is associated with occlusive disease.",
"     </li>",
"     <li>",
"      The presence of calcium in the vessel media may have direct adverse effect on vascular distensibility. The reduced vascular compliance may lead to increased pulse pressure, reduced coronary perfusion, and abnormal autonomic and endothelial vasomotor function. Such overall vascular stiffness may have a profound negative effect upon survival for dialysis patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may well be common risk factors to both types of calcification. These include excess calcium and phosphate, and decreased circulating, or tissue-bound, inhibitors of the calcification process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sevelamer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular problems possibly associated with calcium-based OPBs have in part led to the search for different compounds that can bind phosphate. One such compound is the nonabsorbable agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    (RenaGel), which contains neither calcium nor aluminum. This drug is a cationic polymer that binds phosphate through ion exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .) A new variant of this drug (Renvela) where the hydrochloride moiety is replaced by carbonate, is now available.",
"   </p>",
"   <p>",
"    Several animal and clinical reports have evaluated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    in lowering phosphate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/3,61\">",
"     3,61",
"    </a>",
"    ]. The largest and best designed such clinical trial, which also evaluated progression of vascular calcification, was the \"Treat-to-Goal\" study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/3\">",
"     3",
"    </a>",
"    ]. In this prospective report, 200 patients undergoing maintenance hemodialysis were randomly assigned to sevelamer or calcium-based phosphate binders. In addition, a baseline EBCT image was obtained in 186 individuals, which was followed by EBCT CAC and aortic calcification data among 132 subjects at 6, 12 and (in some patients) 24 months. At one year, although serum phosphate control was similar with both agents (5.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.65",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    calcium-based phosphate binders were associated with a higher incidence of hypercalcemia (16 versus 5 percent) and an increased incidence of low PTH levels (57 versus 30 percent).",
"   </p>",
"   <p>",
"    With respect to vascular calcification, the use of calcium-based OPBs resulted in significant increases in the median absolute calcium scores in assessed vascular beds; this increase was much less pronounced in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    -treated subjects. Compared to the sevelamer group, the calcium group had significantly higher median percent increases in calcium scores for both the coronary artery (25 versus 6 percent) and aorta (28 versus 5 percent).",
"   </p>",
"   <p>",
"    Subsequent analysis found that increased serum concentrations of calcium, phosphate, and the calcium-phosphate product were associated with increased calcium scores among the group who received calcium-based phosphate binders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/62\">",
"     62",
"    </a>",
"    ]. This association was not observed in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    group.",
"   </p>",
"   <p>",
"    The use of calcium-containing oral phosphate binders was therefore clearly associated with rapid and significant progression in CAC as assessed by EBCT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/62\">",
"     62",
"    </a>",
"    ]. This was particularly true in those with poor control of mineral metabolism. However, it is unclear how",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    ameliorated progressive vascular calcification, as the effects on the CAC score did not correlate with any other parameter.",
"   </p>",
"   <p>",
"    Another limitation in accurately interpreting the results of the \"Treat to Goal\" study is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"      calcium acetate",
"     </a>",
"     /carbonate",
"    </span>",
"    differ in lipid-lowering capacity. Unlike calcium-based phosphate binders, sevelamer also has a bile-acid sequestrant effect, thereby reducing lipid absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/3,63-65\">",
"     3,63-65",
"    </a>",
"    ]. In this study, for example, LDL-cholesterol levels decreased by approximately 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/3,63\">",
"     3,63",
"    </a>",
"    ]. In another large study, sevelamer reduced LDL-cholesterol levels by 30 percent, and increased HDL-C cholesterol levels by 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to dissect out the potential mechanism of action of Renagel in the \"Treat-to-Goal\" and RIND studies (in particular to examine the relative contribution of lipid-lowering therapy against phosphate-binding), the CARE-2 study was performed and found similar progression of coronary artery calcification with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the exact clinical effect of lipid lowering with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    is unclear as practically all studies showing cardiovascular benefits from decreased lipid levels have used statins. There is a significant lack of evidence regarding the cardiovascular benefits of lipid lowering with sevelamer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link&amp;anchor=H2#H2\">",
"     \"Statins and chronic kidney disease\", section on 'Physiologic effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is increasing evidence of additional effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    . These include reductions in C-reactive protein (CRP) levels, uric acid levels, and oxidative stress. As an example, subset analysis in the \"Treat to Goal\" study found that, unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    , sevelamer significantly lowered C-reactive protein levels (mean decrease of 4.8",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/66\">",
"     66",
"    </a>",
"    ]. This occurred despite the significantly more frequent use of statins in the calcium acetate group (46 versus 22 percent).",
"   </p>",
"   <p>",
"    Any or all of these alternative mechanisms, in combination with the avoidance of hypercalcemia, may also have contributed to the amelioration of progression of VC in the \"Treat-to-Goal\" study. These properties cannot be assumed to be present in other non-calcium containing OPBs, such as a non-aluminium, non-calcium phosphate binder (eg, ferric chloride) or the rare earth lanthanum chloride. It should be noted that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     Sevelamer",
"    </a>",
"    (like many newer oral phosphate binders) is a relatively expensive drug, with one study suggesting that its widespread use could lead to an additional 781 million dollars spent annually in the United States on this agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relatively less progression of coronary artery calcification with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    has also been observed with incident hemodialysis patients. In this study (referred to as the RIND trial), 129 patients new to hemodialysis were randomly assigned to sevelamer and calcium-containing phosphate binders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/68\">",
"     68",
"    </a>",
"    ]. Among those with coronary artery calcium at dialysis initiation, more rapid and more severe increases in calcification were observed with calcium-containing phosphate binders at 12 and 18 months as assessed by EBCT. Patients on sevelamer were also more likely than those on calcium-containing phosphate binders to show stabilization or regression in coronary artery calcification at 12 months.",
"   </p>",
"   <p>",
"    In addition, a reexamination of the RIND trial suggests a survival advantage to those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    , although a subpopulation of the study who did not show initial cardiac calcification remained free of calcification, despite receiving calcium-containing phosphate binders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the possible decrease in vascular calcification with this agent, a well-designed prospective study, DCOR, found NO difference in cardiovascular mortality or total mortality among hemodialysis patients between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    and a calcium-based phosphate binder. Upon post-hoc subgroup analysis, older patients (&gt;65 years) showed a significantly lower mortality in the sevelamer group. However, this observation must be interpreted with caution. The increased mortality was not due to cardiovascular deaths. In addition, the effect on mortality in the opposite direction for those younger than 65 was just as great but did not achieve significance because of the lower death rates, and therefore a smaller sample, in the younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     K/DOQI guidelines and mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of growing concerns relating to the relationship among cardiovascular disease, VC, and abnormalities in bone and mineral metabolism, a careful process of evidence review and expert deliberation resulted in the 2003",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines on bone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/71\">",
"     71",
"    </a>",
"    ]. Detailed summaries of this review are presented separately within UpToDate. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Based upon this perspective, the following is an overview of some of the general recommendations for patients undergoing maintenance dialysis. In general, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    recommendations are opinions, rather than based directly from evidence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy of elevated phosphate levels (greater than 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&gt;1.8",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      that is refractory to dialysis and diet can be initiated with either calcium or non-metal salt based phosphate binders.",
"     </li>",
"     <li>",
"      The use of a cocktail of oral phosphate binders is strongly encouraged, with a limit of 1.5 grams of calcium salts (making a maximum total of 2 grams of elemental calcium per day in conjunction with dietary calcium intake).",
"     </li>",
"     <li>",
"      Calcium salts should be avoided in patients with sustained intact PTH levels of &lt;150",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      or plasma calcium levels of &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Vitamin D compounds should also be avoided or terminated in patients with calcium levels greater 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Non-calcium-based phosphate binders are preferred in patients with severe vascular or soft-tissue calcifications.",
"     </li>",
"     <li>",
"      Plasma calcium levels should be maintained at the lower end of the normal range (8.4 to 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.1 to 2.35",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      The calcium-phosphate product should be kept less than 55",
"      <span class=\"nowrap\">",
"       mg2/mL2",
"      </span>",
"      (&lt;4.4",
"      <span class=\"nowrap\">",
"       mmol2/L2)",
"      </span>",
"      by first focusing on controlling plasma phosphate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These guidelines favor a general shift away from administering calcium-based phosphate binders. Practically, adherence to these guidelines mandates the use of a variety of different phosphate binders in many patients if the central phosphate control targets are to be achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of the failure of traditional bone disease therapies to permit patients to attain in-target-range values for plasma calcium, phosphate, and PTH levels as well as the calcium-phosphate product have been observed in trials that evaluated the effectiveness of the calcimimetic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    . In these studies, a significant number of patients achieved",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    target levels when cinacalcet was used; by comparison, very few patients administered conventional therapy were able to achieve such levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     KDIGO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 KDIGO",
"    <strong>",
"     clinical",
"    </strong>",
"    practice guidelines were developed to provide recommendations for the evaluation and management of chronic kidney disease-mineral and bone disorder (CKD-MBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/9\">",
"     9",
"    </a>",
"    ]. The term CKD-MBD was created in the attempt to describe the syndrome associated with mineral, bone, and calcific cardiovascular abnormalities. The guidelines were formulated in an attempt to minimize the morbidity and mortality associated with abnormal mineral metabolism, abnormal bone process, and extraskeletal calcification.",
"   </p>",
"   <p>",
"    As such, these guidelines are now the best overview of what we do and do not know about this complex area, and they will now supersede the K-DOQI 2003 guidance which appears to be less relevant. The KDIGO guidelines statement was tremendously difficult to develop and refine, due to the low quality and quantity of evidence available in this important therapeutic area, with very few statements being a firm recommendation based on high quality evidence. Many of the rest of the statements are much more tentative, more akin to suggestions, reminders, and pointers, based on expert opinion or consensus.",
"   </p>",
"   <p>",
"    Compared with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, the KDIGO CKD-MBD guidelines have placed less emphasis on attaining restricted plasma calcium and PTH ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum phosphate should be maintained in the normal range for patients with CKD stages 3 to 5 but not yet on dialysis, and phosphate levels should be lowered to the normal range in those on dialysis.",
"     </li>",
"     <li>",
"      Among dialysis patients, the desired range for PTH should be two to nine times the upper limit of normal reference laboratory range (this is a key change, as the previous K-DOQI range of two to four times normal values was both too low, and too narrow, almost certainly tending to produce adynamic bone states and possibly increased adverse consequences).",
"     </li>",
"     <li>",
"      Plasma calcium levels should be maintained in the normal range.",
"     </li>",
"     <li>",
"      The calcium-phosphate product should not be used to help guide therapy, and its use should be abandoned.",
"     </li>",
"     <li>",
"      Trends in biochemical parameters as well as absolute values should be closely followed.",
"     </li>",
"     <li>",
"      The dose of calcium salts can be considered for restriction in patients with hypercalcemia, adynamic bone disease, vascular calcification",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low serum PTH levels.",
"     </li>",
"     <li>",
"      Not routinely screening all patients for vascular calcification, and, if individual patients need to be assessed for this, reminding clinicians that lateral X-ray of the lumbar spine and echocardiography are excellent tools to use to detect, if not quantify, vascular calcification. CT-based techniques remain best for research.",
"     </li>",
"     <li>",
"      Not routinely using bone densitometry (DXA) scans to assess bone mineral content in CKD stages 3 to 5.",
"     </li>",
"     <li>",
"      In a lengthy passage dealing with binders, therapies, and outcomes, the consensus was that there was not enough evidence of sufficiently robust quality, to make any preferential recommendation of one class or style of oral phosphate binder over any other, and that a slew of factors should be considered (such as clinical, patient preference, economic, etc.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , the use of vitamin D analogs as the primary treatment for hyperparathyroidism in patients with end stage renal disease receiving hemodialysis treatments is undergoing re-evaluation.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    permits the suppression of PTH in patients not adequately controlled with vitamin D analogs, as well as the optimal control of PTH and Ca x P with reduced amounts of vitamin D therapy or even the absence of such therapy. Because of this improved biochemical control (ie, reduced PTH without increased Ca x P), the possibility exists that the use of cinacalcet may reduce vascular calcifications and improve cardiovascular outcomes. Animal data and limited observational studies have suggested that cinacalcet may retard the progression of valvular, aortic and coronary calcification in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    on cardiovascular outcomes is being investigated in the randomized controlled trial \"EVOLVE.\"",
"   </p>",
"   <p>",
"    One caution regarding use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    is the frequent occurrence of hypocalcemia in treated patients. This predictable side effect of PTH inhibition could lead to morbid complications in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\", section on 'Cinacalcet'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, the challenge to control phosphate (the primary goal) remains difficult in the dialysis population. The balance of risk between achieving good phosphate control versus avoiding excess calcium loading has not yet been determined. By comparison, very little can be stated with confidence for pre-dialysis patients, such as when to start phosphate binders, what binders should be utilized, and the target phosphate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role for statins in preventing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treating vascular disease in chronic kidney disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link\">",
"     \"Statins and chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence that renal transplantation may provide benefits relative to CAC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small preliminary study found that renal transplantation appeared to markedly slow down or abolish the progression of",
"      <span class=\"nowrap\">",
"       CAC/VC",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/76\">",
"       76",
"      </a>",
"      ]. In this study, baseline and follow-up CT scans (obtained a minimum of 15 months) were performed in 23 patients who underwent renal transplantation and 17 hemodialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/76\">",
"       76",
"      </a>",
"      ]. Over time, the group that underwent renal transplantation had no change in CAC, while progression was noted in the dialysis group.",
"     </li>",
"     <li>",
"      Among 31 patients who underwent kidney transplantation, CAC progressed over the first six months post-surgery and then stabilized over the next six months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is some evidence that there is significant progression of CAC post-renal transplantation in most subjects. In one study of 82 patients, for example, electron-beam computed tomography of the heart was performed at the time of transplantation and at least one year later [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/78\">",
"     78",
"    </a>",
"    ]. The mean CAC score increased for all subjects, although most subjects (89 percent) with no calcifications remained without calcification.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Additional therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few studies that have evaluated additional agents to help retard or regress VC in patients with renal failure. Some interventions that have been evaluated include bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/79-81\">",
"     79-81",
"    </a>",
"    ] and calcium-channel blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/82\">",
"     82",
"    </a>",
"    ]. One small study also found that subtotal parathyroidectomy significantly decreased or stabilized VC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/83\">",
"     83",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    or high doses of vitamin K to increase the functional ability of Matrix GLA protein to prevent vascular calcification is being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/20/17738/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical practice of inducing a net positive calcium balance via the use of calcium-containing OPBs and vitamin D, as well as the sustained oversuppression of hyperparathyroidism with vitamin D analogs, are sources of concern in the nephrological community. These practices may in part underlie the increased incidence of vascular calcification and enhanced cardiovascular mortality in both non-dialysis-dependent chronic kidney disease patients as well as dialysis patients, although this correlation is somewhat controversial. We feel that the new range for desired PTH concentrations in the 2009 KDIGO guidelines may significantly reduce this risk.",
"   </p>",
"   <p>",
"    Based upon these possible associations, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines encouraged a general shift away from routine administration of calcium-based phosphate binders. The KDIGO guidelines more objectively emphasized the value of phosphate lowering, however achieved, towards the normal range. This important therapeutic area remains pitifully short of good outcome data with suitable interventions.",
"   </p>",
"   <p>",
"    A variety of issues related to coronary artery calcification, vascular calcification, and calcium-based phosphate binders remain unclear. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relationship among CAC, aortic calcium scores, and vessel stiffness (though it is becoming increasingly clear that progressive calcification begets increasing vessel stiffness).",
"     </li>",
"     <li>",
"      The relative contributions to overall vessel deposition of calcium in the vessel wall (eg, diet, dialysate, binders,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone)",
"     </li>",
"     <li>",
"      The importance of aggressive lipid-lowering therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suppression of vascular inflammation over and above phosphate-reduction to impede vascular calcification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link\">",
"       \"Statins and chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      in possibly reducing vascular calcifications and improving cardiovascular outcomes. This will only be answered properly by the EVOLVE study and sub-studies.",
"     </li>",
"     <li>",
"      The complex relationships among plasma calcium and phosphate levels, dialysate calcium concentrations, the use of specific oral phosphate binders, vitamin D type, dose and levels, and the tendency to ectopic calcification.",
"     </li>",
"     <li>",
"      The role of better dialysis strategies (eg, daily especially long-hours hemodialysis where control of plasma phosphate is much superior to conventional hemodialysis).",
"     </li>",
"     <li>",
"      Whether there is a special &ldquo;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      -specific&rdquo; effect on VC that is not shared by other non-calcium containing OPBs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When we do fully comprehend these issues, we will have a better understanding of how (or even if) we should employ CT-based techniques to quantify vascular calcification extent and progression, or to screen for vascular disease in patients with chronic kidney disease. On this point, KDIGO does not mandate routine screening, on account of the fact that there is not a clear-cut, recognized intervention to make, nor any evidence of outcome benefit for so doing. Thus, we feel that it is currently premature to recommend that we screen for,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monitor, vascular calcification in dialysis patients.",
"   </p>",
"   <p>",
"    At present, we feel that is probably premature to recommend more than the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Much greater attention should be made to the successful manipulation of plasma phosphate levels (by better dialysis techniques and better patient education relating to diet and phosphate-binders). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"       \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The avoidance of marked or prolonged positive calcium balance. This includes the more successful calibration of vitamin D administration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adherence to the new KDIGO guidelines for target values for calcium, phosphate, and PTH. (",
"      <a class=\"external\" href=\"file://www.kdigo.org/\">",
"       www.kdigo.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the general strategy related to medical management of coronary artery disease in patients with chronic kidney disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/1\">",
"      Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/2\">",
"      Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/3\">",
"      Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/4\">",
"      London GM, Gu&eacute;rin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/5\">",
"      Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/6\">",
"      Cetinkaya F, Baysal K, Ko&ccedil;ak H, G&uuml;rses N. The incidence and significance of increased backscatter in myocardial ultrasonography of patients on hemodialysis. Nephron 1996; 73:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/7\">",
"      Rostand SG, Sanders C, Kirk KA, et al. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988; 85:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/8\">",
"      Cesani F, Villanueva-Meyer J. Intense myocardial and lung uptake of 99m-Tc-pyrophosphate using single photon emission computed tomography in a patient with end-stage renal disease and secondary hyperparathyroidism. Int Urol Nephrol 1996; 28:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/9\">",
"      KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/10\">",
"      K/DOQI clinical practice guidelines for cardiovacular disease in dialysis patients. Am J Kidney Dis 2005; 45(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/11\">",
"      Bryant, JH, Hale, White, W. A case of calcification of the arteries and obliterative endarteritis, associated with hydronephrosis, in a child aged six months. Guys Hosp Rep 1901; 40:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/12\">",
"      Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet 1968; 2:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/13\">",
"      Rees JK, Coles GA. Calciphylaxis in man. Br Med J 1969; 2:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/14\">",
"      Mulligan, RM. Metastatic calcification. Arch Pathol 1946; 42:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/15\">",
"      POLLAK VE, SCHNEIDER AF, FREUND G, KARK RM. Chronic renal disease with secondary hyperparathyroidism. AMA Arch Intern Med 1959; 103:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/16\">",
"      Parfitt AM. Soft-tissue calcification in uremia. Arch Intern Med 1969; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/17\">",
"      Kuzela DC, Huffer WE, Conger JD, et al. Soft tissue calcification in chronic dialysis patients. Am J Pathol 1977; 86:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/18\">",
"      Terman DS, Alfrey AC, Hammond WS, et al. Cardiac calcification in uremia. A clinical, biochemical and pathologic study. Am J Med 1971; 50:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/19\">",
"      Ibels LS, Alfrey AC, Huffer WE, et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/20\">",
"      Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/21\">",
"      Meema HE, Oreopoulos DG, deVeber GA. Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology 1976; 121:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/22\">",
"      Meema HE, Oreopoulos DG. Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology 1986; 158:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/23\">",
"      Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/24\">",
"      Andresen JH, Nielsen HE. [Extraskeletal calcification in chronic renal failure during hemodialysis and after renal transplantation (author's transl)]. Klin Wochenschr 1982; 60:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/25\">",
"      Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/26\">",
"      McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/27\">",
"      Schwaiger JP, Neyer U, Sprenger-M&auml;hr H, et al. A simple score predicts future cardiovascular events in an inception cohort of dialysis patients. Kidney Int 2006; 70:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/28\">",
"      Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001; 38:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/29\">",
"      Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/30\">",
"      Stomp&oacute;r T, Pasowicz M, Sul��owicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/31\">",
"      Eifinger F, Wahn F, Querfeld U, et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 2000; 15:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/32\">",
"      Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/33\">",
"      Moe SM, O'Neill KD, Fineberg N, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/34\">",
"      Sharples EJ, Pereira D, Summers S, et al. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis 2004; 43:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/35\">",
"      Merjanian R, Budoff M, Adler S, et al. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/36\">",
"      Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/37\">",
"      Kramer H, Toto R, Peshock R, et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/38\">",
"      Qunibi WY, Abouzahr F, Mizani MR, et al. Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int 2005; 68:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/39\">",
"      Russo D, Palmiero G, De Blasio AP, et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/40\">",
"      Chiu YW, Adler SG, Budoff MJ, et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010; 77:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/41\">",
"      Ix JH, Katz R, Kestenbaum B, et al. Association of mild to moderate kidney dysfunction and coronary calcification. J Am Soc Nephrol 2008; 19:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/42\">",
"      Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/43\">",
"      O'Neill WC, Lomashvili KA, Malluche HH, et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/44\">",
"      Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/45\">",
"      Coladonato JA, Szczech LA, Friedman EA, Owen WF Jr. Does calcium kill ESRD patients--the skeptic's perspective. Nephrol Dial Transplant 2002; 17:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/46\">",
"      Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 2000; 6:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/47\">",
"      Shioi A, Mori K, Jono S, et al. Mechanism of atherosclerotic calcification. Z Kardiol 2000; 89 Suppl 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/48\">",
"      Mallick NP, Berlyne GM. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 1968; 2:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/49\">",
"      Irnell L. Metastatic calcification of soft tissue on overdosage of vitamin D. Acta Med Scand 1969; 185:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/50\">",
"      Braam LA, Hoeks AP, Brouns F, et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/51\">",
"      Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/52\">",
"      Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/53\">",
"      Goldsmith D, MacGinley R, Smith A, Covic A. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 2002; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/54\">",
"      London GM, Marchais SJ, Guerin AP, et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/55\">",
"      Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/56\">",
"      Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/57\">",
"      Lockhart ME, Robbin ML, McNamara MM, Allon M. Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients. Nephrol Dial Transplant 2004; 19:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/58\">",
"      Savage T, Clarke AL, Giles M, et al. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 1998; 13:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/59\">",
"      Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/60\">",
"      Bonifacio DL, Malineni K, Kadakia RA, et al. Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk 2001; 8:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/61\">",
"      Mathew S, Lund RJ, Strebeck F, et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/62\">",
"      Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/63\">",
"      Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/64\">",
"      Burke SK, Dillon MA, Hemken DE, et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/65\">",
"      Katopodis KP, Andrikos EK, Gouva CD, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int 2006; 26:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/66\">",
"      Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/67\">",
"      Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004; 66:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/68\">",
"      Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815.",
"     </a>",
"    </li>",
"    <li>",
"     Block, GA, Raggi, P, Bellasi, A, Kooienga, L, Spiegel, DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007 71:438.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/70\">",
"      Silver J. The details bedevil DCOR. Kidney Int 2007; 72:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/71\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/72\">",
"      Covic A, Kanbay M, Voroneanu L, et al. Vascular calcification in chronic kidney disease. Clin Sci (Lond) 2010; 119:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/73\">",
"      Aladr&eacute;n Regidor MJ. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol 2009; 71:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/74\">",
"      Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/75\">",
"      Lopez I, Mendoza FJ, Guerrero F, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009; 296:F1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/76\">",
"      Moe SM, O'Neill KD, Reslerova M, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004; 19:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/77\">",
"      Oschatz E, Benesch T, Kodras K, et al. Changes of coronary calcification after kidney transplantation. Am J Kidney Dis 2006; 48:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/78\">",
"      Schankel K, Robinson J, Bloom RD, et al. Determinants of coronary artery calcification progression in renal transplant recipients. Am J Transplant 2007; 7:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/79\">",
"      Rosenblum IY, Black HE, Ferrell JF. The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tissue Res 1977; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/80\">",
"      Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/81\">",
"      Hashiba H, Aizawa S, Tamura K, et al. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 2004; 8:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/82\">",
"      Fleckenstein-Gr&uuml;n G, Thimm F, Frey M, Matyas S. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats. J Cardiovasc Pharmacol 1995; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/20/17738/abstract/83\">",
"      Bleyer AJ, Burkart J, Piazza M, et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46:464.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7222 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17738=[""].join("\n");
var outline_f17_20_17738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION AND QUANTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOW NEW IS THE EPIDEMIC OF VASCULAR CALCIFICATION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autopsy studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CT studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MINERAL METABOLISM AND VASCULAR CALCIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcium intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General alterations in mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vitamin D therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL IMPLICATIONS OF VC IN CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sevelamer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      K/DOQI guidelines and mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      KDIGO guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Additional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=related_link\">",
"      Biology of vascular calcification in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_20_17739="Risk of a 3rd preterm birth";
var content_f17_20_17739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of recurrent preterm birth in a third pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Obstetrical history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of PTB (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Two prior preterm births",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Both at 32 to 36 weeks",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Both at less than 32 weeks",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Term birth followed by PTB",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTB followed by term birth",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two prior term births",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTB: preterm birth.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007; 196:576.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17739=[""].join("\n");
var outline_f17_20_17739=null;
var title_f17_20_17740="New single agts chemo";
var content_f17_20_17740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Studies evaluating newer single agents chemotherapy in locally advanced and metastatic esophageal and gastric cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cancer type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Author",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       RR (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Paclitaxel 24 hour infusion",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Ajani, J; 1994",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Ajani, J; 1998",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Paclitaxel weekly short infusion",
"      </td>",
"      <td>",
"       Esophageal",
"      </td>",
"      <td>",
"       Ilson, D; 2007",
"      </td>",
"      <td>",
"       102",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Kii, T; 2006",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Docetaxel",
"      </td>",
"      <td>",
"       Esophageal (1st and 2nd-line)",
"      </td>",
"      <td>",
"       Muro, K; 2004",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Mavroudis, D; 2000",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Irinotecan",
"      </td>",
"      <td>",
"       Esophagogastric",
"      </td>",
"      <td>",
"       Enzinger, P; 2005",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric",
"      </td>",
"      <td>",
"       Kohne, C; 2003",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Vinorelbine",
"      </td>",
"      <td>",
"       Esophageal SCC (1st and 2nd-line)",
"      </td>",
"      <td>",
"       Conroy, T; 1996",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophagogastric adenocarcinoma (1st and 2nd line)",
"      </td>",
"      <td>",
"       Kulke, M; 2006",
"      </td>",
"      <td>",
"       29",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: number of patients; RR: objective response rate.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fidias, P, El-Karak, FR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17740=[""].join("\n");
var outline_f17_20_17740=null;
var title_f17_20_17741="Differential diagnosis of apparent life-threatening event";
var content_f17_20_17741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of an apparent life-threatening event (ALTE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal (misinterpreted as abnormal behavior)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular breathing of REM sleep in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periodic breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory pauses (5-15 sec), and longer pauses after sigh",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient choke, gag, cough during feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sepsis, meningitis, encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory syncytial virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pertussis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other respiratory infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Volvulus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intussusception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drug effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unintentional or intentional ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Metabolic decompensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary inborn error of metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Secondary to other endocrine, electrolyte, or metabolic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Toxic exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Child abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-accidental suffocation, forced aspiration, intoxication, or physical injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factitious illness (Munchausen syndrome by proxy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastroesophageal reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Swallowing incoordination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breath-holding spells or variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reflex apnea with stimulation of laryngeal chemoreceptors during aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital airway anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormalities of respiratory control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immaturity or prematurity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central hypoventilation syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vocal cord dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Laryngotracheomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vascular ring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasovagal syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other neurologic conditions affecting respiratory control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apnea associated with Chiari or other hindbrain malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     REM: rapid eye movement; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17741=[""].join("\n");
var outline_f17_20_17741=null;
var title_f17_20_17742="Contents: Substance use disorders";
var content_f17_20_17742=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Substance use disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Substance use disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alcohol abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/22/2409\">",
"           Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4361\">",
"           Ambulatory alcohol detoxification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/17/42265\">",
"           Brief intervention for unhealthy alcohol and other drug use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/13/15577\">",
"           Identification and management of alcohol use disorders in the perioperative period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/8/17544\">",
"           Nutritional status in alcohol dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/48/19209\">",
"           Pharmacotherapy for alcohol abuse and dependence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41847\">",
"           Psychosocial treatment of alcohol abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-specific abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32970\">",
"           Cocaine abuse and dependence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/24/22920\">",
"           Methamphetamine abuse and dependence: Epidemiology, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3784\">",
"           Opioid abuse and dependence: Overview and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1191\">",
"           Opioid detoxification during treatment for addiction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27160\">",
"           Prescription drug abuse and addiction: Prevention, identification, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25993\">",
"           Screening for unhealthy use of alcohol and other drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29514\">",
"           Treatment of opioid abuse and dependence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2936\">",
"           Clinical management of substance dependence across the continuum of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41177\">",
"           Co-occurring anxiety disorders and substance use disorders: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36521\">",
"           Dual diagnosis: Severe mental illness and substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5562\">",
"           Impaired healthcare provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2313\">",
"           Motivational interviewing for substance use disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/19/9529\">",
"           Non-hormonal performance enhancement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36535\">",
"           Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/58/5033\">",
"           Substance use disorders: Principles for recognition and assessment in general medical care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29993\">",
"           Treatment of co-occurring anxiety disorders and substance use disorders",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C27E3A63B8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_20_17742=[""].join("\n");
var outline_f17_20_17742=null;
var title_f17_20_17743="Hyperplastic gastric polyps UGI";
var content_f17_20_17743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperplastic gastric polyps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast upper gastrointestinal study shows multiple well-circumscribed uniformly sized hyperplastic polyps arising from the gastric mucosa (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_20_17743=[""].join("\n");
var outline_f17_20_17743=null;
